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Abstract. In this whitepaper, the Manufacturing Technical Committee of the Product Quality Research
Institute provides information on the common, best practices in use today in the development of high-
quality chemistry, manufacturing and controls documentation. Important topics reviewed include Inter-
national Conference on Harmonization, in vitro–in vivo correlation considerations, quality-by-design
approaches, process analytical technologies and current scale-up, and process control and validation
practices. It is the hope and intent that this whitepaper will engender expanded dialog on this important
subject by the pharmaceutical industry and its regulatory bodies.
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INTRODUCTION
In 1991–1992, three scientific organizations—the Ameri-
can Association of Pharmaceutical Scientists, the Food &
Drug Association (FDA), and the United States Pharmaco-
peia (USP)—collaborated to organize two workshops to ex-
plore the Scale-Up and Post-approval Change (SUPAC)
principles for (1) immediate-release oral solid dosage forms
(1991) and (2) oral extended-release dosage forms (1992).
Proceedings from both workshops were published in 1993
(1,2) and have been used as guidance to the industry and
regulatory bodies. The proceedings of both workshops
discussed and defined the impact of (1) formulation or com-
positional changes, (2) process variable changes, (3) process
scale changes, and (4) process site changes on the finished
quality parameters of these products. Each area of change was
further divided to reflect a hierarchy of “significance” and
hence aided in establishing post-approval change filing
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documentation. In the case of the extended-release dosage
forms, the potential need for the conduct of one or more
pivotal bioavailability/bioequivalence (BA/BE) studies was
recognized and, as a result, included a recommended decision
tree to determine when a BE study would be needed to prove
equivalence.
Although these documents continue to have utility in
supporting post-approval changes, it has been recognized that
there have been many improvements implemented in the
scale-up and control of both immediate-release and extend-
ed-release oral solid dosage forms in the last two decades. It is
the goal of the authors of this whitepaper to provide a concise
updating of important development principles currently avail-
able to those in the industry involved in the development of
such products. Accordingly, this whitepaper will present com-
prehensive chemistry, manufacturing, and controls (CMC)
information to those involved in the development and review
of oral solid dosage form dossiers. It is our hope that the
added information will lead to improved process for post-
approval changes. While much of this information is available
in official guidance documents, for example, International
Conference on Harmonization (ICH) and quality-by-design
(QbD) documents, it is a goal of this whitepaper to bring all
of the independent pieces into a unified document to facilitate
improved understanding and implementation.
This whitepaper, sponsored by the Product Quality Re-
search Institute, is a result of that thinking and is designed to
engender additional discussion and commentary from experts
within the industry, academia, and worldwide regulatory bod-
ies. Although the document retains the spirit of the original
workshop reports, it encourages the inclusion of new tools for
the development, testing, and control of oral solid dosage
forms. The use of tools and approaches such as process ana-
lytical technologies (PATs), QbD, in vitro–in vivo correlation
(IVIVC), and more thorough excipient characterization
should improve the robustness of the finished products and
minimize or prevent unintended drift in the quality of the
affected commercial drug products.
It should be noted that these best practices, as outlined in
this paper, are only applicable to QbD-based applications.
They cannot be used for legacy or mature products which
were not developed using the new systematic and life cycle
approaches. The principles of QbD are mainly in use in Can-
ada, Europe, Japan, and the USA, but are gaining recognition
in other countries as well.
REVIEW OF THE 1993 ORAL SOLID DOSAGE FORM
WORKSHOP REPORT FINDINGS
We begin our oral solid whitepaper with a brief review of
the salient findings of the 1993 publications.
Compositional Variables
In 1993, it was recognized that oral solid dosage forms
contained both “noncritical” and “critical” components and
that it was the job of the formulating scientist to establish
(with data) which excipients fell into each category. Further-
more, it was recognized that for noncritical excipients, for both
immediate- and extended-release (ER) products, “certain
compositional adjustments (to formulations) were determined
to be acceptable, without further justification” (2). The report
also noted that “there is, however, an additional consideration
for extended-release dosage forms: the inclusion of a critical
release component(s) which enables the extended release of
active ingredients. Thus, for extended-release dosage forms,
consideration must be given as to whether the component is
critical or not critical to drug release” (2). The passage of time
has certainly confirmed the validity of these statements.
The authors have undertaken within this whitepaper to
include a review of the current tools in place that allow phar-
maceutical scientists and regulators to evaluate whether a
change is critical or not critical.
Using tools in place today such as QbD approaches that
explore and understand the relationships between target prod-
uct parameters and end product quality attributes, our con-
tributors believe that more robust products will result. We also
feel that the use of the current improved statistical design
packages when combined with QbD approaches can afford
substantial information about the allowable range of both
minor excipients/components and those that are critical to
product performance. In addition, the use of these approaches
when combined with improved testing techniques associated
with PAT and enhanced finished product testing such as
in vitro release can and should be used to facilitate review
and approval of post-approval CMC submissions involving
compositional variables. Each of these techniques will be
discussed fully in subsequent sections of this whitepaper.
Process Variables
Since 1993, substantial progress has been made by the
pharmaceutical industry in the development of robust
manufacturing processes. Techniques such as PAT are becom-
ing more common in process control of manufacturing opera-
tions and in continual feedback and feed-forward loops that
adjust manufacturing operations, thereby providing a more
consistent end product. In parallel, improvements to end
product testing results, including enhanced statistical tools,
have further increased the ability of companies to manufac-
ture more consistent products and to monitor and control
variation. Today’s pharmaceutical scientist also has greatly
improved statistical design tools with which to proactively
develop and test formulation and manufacturing process pa-
rameters. Our collaborators have elaborated on these control
strategies in several sections of this whitepaper.
In Vitro Tests
In vitro testing was common in 1993 and was regarded as
“a basic quality control tool used along with stability data to
control scale-up and post-approval changes” (1). In this
whitepaper, we review modernization of those techniques
and the testing equipment used to monitor in vitro drug re-
lease, with an end goal of facilitating the development of
IVIVCs that can be used to expedite post-approval changes.
In Vitro/In Vivo Correlation
The 1993 Workshop Report on extended-release dosage
forms stated that “in order to utilize an IVIVC, the adequacy
of the in vitro method to act as a surrogate for in vivo testing
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must be demonstrated” (2). In the two decades that have
followed, a number of IVIVCs have been developed. The
current state-of-the- art approaches to IVIVC development
are reviewed within this whitepaper in order to encourage
further development of this important tool.
In addition to providing a brief review of all of the major
tools in place today that are useful to the pharmaceutical
scientist involved in the development of immediate- and ex-
tended-release oral solid dosage forms, our whitepaper con-
tributors have included brief commentary on what they see as
developing trends that could bring new exciting tools to bear
on these issues in the next 3–5 years.
CURRENT PRINCIPLES THAT AFFECT IR AND MR
PRODUCT DEVELOPMENT
Introduction and Current State
The Federal Food, Drug, and Cosmetic Act and the Code
of Federal Regulations (Section 314.70(a)(2)) state that the
applicant holds the final responsibility for determining the
effects of a change on the drug product as it relates to the
product’s safety and efficacy before distributing the drug prod-
uct made with a manufacturing change. When the safety as-
pect of the product is brought into question as a result of a
change, a prior approval supplement is called for, irrespective
of the suggested filing category for that change. Other than for
minor editorial changes such as spelling corrections or
reformatting batch records, etc., the applicant must notify
the FDA about each change that is made beyond the range
that is allowed for that change in the approved application
(Section 314.70(a)(1)).
A Supplement or Annual Report must include a list of all
changes contained in the document. The list must describe
each change in sufficient detail so that the agency can make
an objective assessment on the appropriateness of the
reporting category used. For supplements, the list must be
provided in the cover letter (Section 314.70(a)(6)); for annual
reports, the list should be included in the Summary
Section (Section 314.81(b)(2)(i)). Each change must be de-
scribed in complete detail inside the document.
Available post-approval regulatory documents in the
USA cover a range of topics, but are more focused on drug
product and changes associated with drug product manufac-
ture. There are some regulatory guidance documents in the
USA that cover drug substance changes, but are fairly limited
in scope. A few FDA guidance documents issued were specific
to drug substance, e.g., Bulk Active Compound Post-approval
Change (BACPAC) 1, but have since been withdrawn. Thus,
there is a pressing need for active pharmaceutical ingredient
(API)-focused guidance documents for post-approval changes
in the USA.
Changes to the drug substance control strategy may be
subject to post-approval change requirements, as stipulated in
FDA guidance documents. For example, changes to the drug
substance manufacturing process require the submission of a
prior approval supplement as defined under computer-
assisted NDA (CANDA) requirements, unless the change is
covered by an approved design space in the New Drug Appli-
cation (NDA).
The availability of ICH Q7 and Q11 guidance documents
has relieved the current gap in a limited way. However, post-
approval changes and submissions pathways to handle those
changes are quite regional in nature, and these guidance doc-
uments do not address that issue. Several guidance documents
have been issued by non-US regulatory agencies [e.g., EC
communication on variations (3) and Health Canada guidance
on post-notice of compliance (NOC) changes (4)] that offer
valuable insight into the regulatory pathways (ex-US) to sub-
mitting post-approval changes.
ICH Initiatives (Q8, Q9, Q10, Q11)
The FDA’s Critical Path Initiative (5) triggered the de-
velopment of new quality paradigms in the pharmaceutical
industry, including the concept of QbD. The FDA’s ultimate
goal was to transform its CMC review practices into a science
and risk-based pharmaceutical quality assessment system
which could potentially lead to an increase in the number of
successful new applications and a reduction in the number of
post-approval supplements.
Specifically, the FDA’s objectives were to:
– Encourage early adoption of new technological advances by
the pharmaceutical industry
– Facilitate industry application of modern quality manage-
ment techniques, including implementation of quality systems
approaches, to all aspects of pharmaceutical production and
quality assurance
– Encourage implementation of risk-based approaches that
focus both industry and the agency attention on critical areas
– Ensure regulatory review and inspection policies are based
on state-of-the-art pharmaceutical science
– Enhance consistency and coordination of the FDA’s drug
quality regulatory programs, in part, by integrating enhanced
quality systems approaches into the agency’s business process-
es and regulatory policies concerning review and inspection
activities
These objectives are reflected in the ICH’s Q8, Q9, and
Q10 guidance documents.
Any discussion on QbD necessitates defining pharmaceu-
tical quality, which is rather subjective. ICH defines drug
quality as the ability of a product to satisfy stated needs,
including identity, strength, and purity, without undesired side
effects (6).
Historically, the relationship of product quality to product
attributes has not been well defined or understood. As a
consequence, the FDA has ensured product quality via tight
specifications based on the observed properties of clinical and/
or technical batches and by limiting the changes that can be
made within manufacturing processes (7).
In considering post-approval changes to an approved
NDA or abbreviated New Drug Application (ANDA), cur-
rent guidelines do not readily allow for the consideration of
risk-based and science-based approaches for regulatory deci-
sion making. The guidelines were not developed based on a
thorough understanding of the manufacturing process, prior
knowledge and experience from similar types of products, and
overall quality in determining whether a submission is re-
quired. Current guidelines recommend manufacturers to as-
sess the effects of manufacturing changes on identity, strength,
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quality, purity, and potency of a drug as they relate to the
safety or effectiveness of a product.
This rather prescriptive approach has contributed to
pharmaceutical companies being reluctant to change their
manufacturing processes and equipment from time to time
from a continuous improvement perspective. The current
SUPAC Guidance for Immediate- and Modified-Release solid
oral dosage forms permits manufacturers to determine the
submission requirements and category based on a predefined
algorithm of information and data.
The introduction of the ICH Quality Guidelines, Q8 (R2),
Q9, and Q10, and Q11 are intended to help develop a science-
and risk-based approach to quality and, at the same time, en-
courage continuous improvement as part of a product’s life cycle
through an effective pharmaceutical quality control system.
Furthermore, the FDA’s Manual of Policies and Proce-
dures (MAPP), specifically MAPP5016.1, outlines and clar-
ifies how the CMC reviewers in the Office of New Drug
Quality Assessment in the Office of Pharmaceutical Science
should apply the guidance recommendations to the review of
regulatory submissions (8).
Since the ICH Guidance documents have been reviewed
extensively elsewhere, they are assumed to be part of the work-
ing knowledge of our readers and will not be reiterated within
this whitepaper other than to list their main topic areas, namely,
– ICH Q8 (R2)—Pharmaceutical Development (9)
– ICH Q9—Quality Risk Management (10)
– ICH Q10—Pharmaceutical Quality System (11)
– ICH Q11—Development and Manufacture of Drug Sub-
stances (Chemical Entities and Biological/Biological Entities)
(12)
The concept of design space for pharmaceutical manufac-
ture was suggested in the Guidance for Industry—PAT—A
Framework for Innovative Pharmaceutical Development,
Manufacturing and Quality Assurance (13). The definition of
design space was provided in ICH Q8 (R2) as a multidimen-
sional combination and interaction of input variables such as
material attributes and process parameters that have been dem-
onstrated to provide assurances of quality. Working within such
a design space should not be considered a change. The identifi-
cation of the material attributes and critical process parameters
is important in describing the boundary of a design space.
Movement outside a design space is generally considered
a change which would normally initiate a regulatory post-
approval change process. Using the principles in ICH Q9,
the level of risk when assessing a change scenario requires
sufficient information and detail on how the risks were iden-
tified, characterized, and evaluated to clearly convey a full
understanding of the decision-making process and the impact
of any subsequent decision in a given product or process
change. Combining these risk principles to assess control,
communicate, and review quality risks, with prior knowledge
and understanding, it should be possible under the principles
of a robust quality system as outlined in Q10 to determine,
using sound scientific knowledge and judgment, the potential
impact on patient safety and efficacy.
This should provide opportunities for determining the
appropriate regulatory approach to a given product or process
change and still meet the requirements as outlined in the 21
CFR 314.70 which outlines current requirements for changes
to an approved NDA or ANDA (Prior Approval Supplement,
CBE/CBE-30 or Annual Report) (14).
FDA Guidance
Changes to an Approved NDA or ANDA
An FDA-issued guidance (15,16) makes recommenda-
tions for post-approval changes in components and composi-
t ion, manufacturing sites , manufacturing process ,
specifications, container closure system and labeling, as well
as multiple related changes. This guidance does not provide
recommendations on specific information required to assess
the effect of changes to identity, strength, purity, or potency of
a drug product. In general, it discusses three types of changes:
major changes which have a substantial potential to have an
adverse effect on product quality attributes of identity,
strength, quality, purity, or potency as they relate to the safety
and efficacy of a drug product; moderate changes which have
a moderate potential to affect product quality attributes; and
minor changes which would have a minimal potential to ad-
versely impact product quality attributes.
CMC Post-approval Manufacturing Changes Reportable in
Annual Reports
In an attempt to reduce the number of manufacturing
supplements in recent years, in connection with FDA’s Phar-
maceutical Product Quality Initiative, and incorporating a
risk-based approach to the CMC review process, a list of
post-approval manufacturing changes (16) that can be report-
ed in an Annual Report was developed. This listing includes
changes to components and compositions, manufacturing sites
and processes, along with specifications, container closure
systems, and miscellaneous changes.
Canada, Europe, Japan, and the Rest of the World’s
Countries
While the SUPAC Guidance is specifically considered a
US-only guidance, it is viewed favorably by some other regu-
latory authorities, and aspects of it are incorporated as part of
their country-specific post-approval change regulatory
requirements.
As many companies develop products with a global per-
spective, there are other guidance documents that may be
considered when making post-authorization changes to ap-
proved immediate- and modified-release products.
Canada
NOC Changes—Quality Guidance Appendix 1 for Hu-
man Pharmaceuticals, Canada Ministry of Heath, Health Prod-
ucts and Food Branch. This guidance, implemented 17
October 2011 (4), outlines the categorization of post-approval
changes and makes recommendations for supporting docu-
mentation based on the level of risk. This revised document
simplifies the process for submitting post-authorization chang-
es in manufacturing and chemistry which require Health Can-
ada approval. This revision eliminates level II (Notifiable
Change) and moves higher-risk submissions to level I while
668 Van Buskirk et al.
moving lower-risk changes to level III. The intent of this
revision was to provide greater clarity for filing requirements
of supplements without affecting safety and efficacy.
The data requirements associated with the changes
outlined in the PNOC-QD are based on (commensurate to)
the level of existing knowledge and established assurance of
quality of a product afforded by an NOC and, in many cases,
also by market manufacturing experience.
Where there are differences between Health Canada data
requirements to support pre- and post-NOC changes, spon-
sors are expected to include information and data in their
submission in accordance with pre-NOC guidance documents
(17,18) rather than with the PNOC-QD.
European Medicines Agency
In the EU, amendments to an approved application are
called variations. In 2003 (19), the Variations Guidance was
amended; the intent was to simplify reporting procedures and,
at the same time, provide the same regulatory framework for
changes in both the mutual recognition and the centralized
procedures.
There are three categories of post-approval variations
(3). Type 1A variations are considered minor changes. Such
changes are simply administrative in nature or other modifi-
cations which do not affect the quality, safety, or efficacy of the
product. There are two subcategories of 1A variations, which
have clearly defined document requirements and set of con-
ditions for the change
Type 1A variations are “do and tell.” Generally, the IA
variations can be submitted within 12 months of implementa-
tion. These 1A variations will be equivalent to the US annual
reports. There is also a type IA(IN) variation where immedi-
ate notification is required upon implementation. This is sim-
ilar to the US CBE.
Type 1B variations require notification of changes before
implementation. Regulatory approval is expected within
30 days of submission for changes that are considered more
scientifically minor in impact. Type 1B variations are given as
examples rather than as set criteria and conditions. There is a
1B default classification for changes that are neither a 1A nor
a type II variation. The idea behind type 1B changes is to create
flexibility for industry, but with that flexibility come the chal-
lenges due to the lack of clearly defined requirements. Type 1B
variations are essentially equivalent to the US CBE 30.
There is also an “unforeseen” variation approach for
those variations that are not listed in either the guideline or
the regulation and for which the type IB by default is uncer-
tain or controversial and believed to be a lower category than
a type II variation. The Ministry of Health may request the
CMDh (Co-ordination Group for Mutual Recognition and
Decentralised Procedures—Human) to provide a recommen-
dation on the classification of the variation according to Arti-
cle 5 of the regulation. Timings of this process can be
equivalent to timings of a type II change, so one really needs
to make sure there is a need to have a change classified.
Type II variations are for major changes not meeting the
criteria for minor variations and line extensions. Type II var-
iations are the severest category and will be prior approval
change, similar to the US SNDA. The approval timing for a
type II variation is typically 3–6 months.
In an attempt to further simply these variation classifica-
tions, the European Commission (EC) has proposed current
amendments to the current regulations (20).
One difficulty in dealing with the EU is that there are a
number of different marketing approvals that exist in Europe,
i.e., centralized, decentralized, and national, and the adminis-
trative reporting burden varies with the different approval
processes.
Japan
Japan revised its pharmaceutical Affairs Law in 2002
which amended its procedures for post-approval changes. De-
pending on the nature of the change, the requirements can be
quite extensive, with a lengthy review time. Items noted as
minor do not require pre-approval and can be submitted as
notifications (21).
Quality By Design Principles
Importance of TPPs and QTPPs in Product Development
Proactive Identification and Definition of Desired Target
Product Quality. A quality target product profile (QTPP)
relates to the required quality of a drug product or drug
substance that is necessary to deliver a desired therapeutic
effect. When prepared proactively, the QTPP serves as a
set of predefined objectives establishing product and pro-
cess deliverables that will provide the greatest benefit for
attaining the critical attributes that impact drug product
quality. These predefined QTPPs evolve over time during
drug development and may be modified to incorporate
new knowledge, as is warranted by ongoing clinical stud-
ies; such as dose effect and toxicology data that are often
conducted in parallel with a product’s developmental
activities.
Clinical, Patient, Marketing Alignment. The QTPP com-
prised all the necessary attributes a product needs to
deliver in order to meet its intended use. A product’s
QTPP provides guidance for linking its process, formula-
tion, and incoming materials with therapeutic patient out-
comes. Examples of clinically relevant QTPPs include, but
are not limited to, dosage form and biorelevant data,
dosing regimen that achieves a predefined clinical result,
pharmacokinetics (PK), bioequivalence, and established
efficacy and safety profiles (9). In order to maximize
ultimate product performance, other attributes of a drug
product may also be considered, such as product identify
(tablet size, shape, and color) and intended patient
population.
QTPP and Risk Assessment. Once all of the components
of a QTPP have been defined, a preliminary risk assessment
should be completed before starting development activities.
This allows for revision of the QTPP, if needed, and guides
development activities prior to investment of major develop-
ment resources. It is important to note that risk assess-
ments should be updated as further knowledge is gained
during development.
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Importance of CQAs in Product Development
Align with QTPP. Once a product’s QTPP is defined,
the appropriate formulation and process characteristics of
the product can be developed around it. The attributes
that assess the quality of the drug product or drug sub-
stance aligned with the QTPP are referred to as the
critical quality attributes (CQAs). They link the product’s
quality with its desired therapeutic performance. Similar
to QTPPs, when CQAs are proactively identified, estab-
lishment of target process deliverables can be prepared
and alignment with therapeutic targets achieved. Where
QTPPs are derived based on desired clinical responses,
CQAs are those characteristics that reflect the final pro-
cess and product quality. For example, where bioavailabil-
ity is an element of a product’s QTPP, dissolution may be
its associated CQA. Although the CQAs are deemed
product quality- and/or process-relevant, it is important
to understand how they can potentially affect patient
therapeutic outcomes when establishing ”acceptable” spec-
ification ranges. In this manner, the QTPP guides the
selection of appropriate CQA specifications (or specifica-
tion ranges) based on those critical attributes ultimately
necessary for delivering the desired patient effect.
Changes made to the QTPP during development will
necessitate corresponding changes to the product’s critical
manufacturing attribute(s) (CMAs), critical process parame-
ters (CPPs) and CQAs.
Process-Delivered Responses. The CQAs that define the
drug product QTPP typically include assay, dissolution results,
stability, impurity profile, microbial burden, and physical ap-
pearance. Presently, CQAs are similar to the drug product and
drug substance release and stability specifications as they
traditionally reflect the desired patient deliverables. However,
CQAs are potentially influenced by multivariate parameters,
which themselves may interact with other parameters or ma-
terial attributes throughout the manufacturing process. There-
fore, as the development process evolves, new knowledge may
be uncovered that challenges earlier conclusions. This re-
quires that CQAs are updated throughout the product devel-
opment processes. An example is the possible shift of a CQA
from dissolution to disintegration time (DT) for an immediate-
release (IR) dosage form. As development proceeds and addi-
tional knowledge gained, it may become apparent that DT is a
better quality surrogate than the traditional dissolution.
Correlation to CPPs. Process understanding through
identification of potentially influential variables (such as
process parameters, material attributes, drug substance
quality, etc.) on CQAs is an integral aspect of the phar-
maceutical development process. Those variables that
have an impact (i.e., elicit a significant response) on a
CQA(s) are deemed “critical.” When assessing criticality,
it is helpful to have predetermined criteria for signifi-
cance. For example, is a 3% impact on dissolution of an
IR or modified-release (MR) product considered signifi-
cant or can the impact be explained by the inherent
variability of the analytical method? In-process attributes
may be more challenging to define. Examples such as
blend or granulation flowability (via Carr index or
Hausner ratio), while easy to quantify, may be difficult
to establish as a predetermined critical metric, especially if
such attributes are not commonly monitored/studied and
therefore no basis of comparison is available. It is impor-
tant for the formulation scientist to evaluate how much
variability in the associated attribute could elicit a re-
sponse which can ultimately impact product quality. Un-
derstanding the main effects that critical process parameters,
material attributes, and their mutual interactions have on a
product’s defined CQA(s) is important in order to establish
control of the CQAs and, ultimately, the final product quality
(22).
Importance and Demonstration/Determination of CPPs
and Resulting Design Space
Correlation and Alignment to Specific CQAs (Cause/Ef-
fect Relationship). CQAs provide the link between critical
formulation and process parameters with clinical product per-
formance. Therefore, all critical sources of variability inherent
in a formulation or process should be identified and under-
stood and a rationale established on how they will be managed
going forward.
Once an understanding of critical process parameters and
material attributes is established for those variables that affect
respective CQAs, deeper knowledge can be developed re-
garding the magnitude of effects. Ultimately, this helps estab-
lish the appropriate ranges of the multivariate design space. In
order to attain this level of cause–effect understanding, one
needs to establish a correlation of the CPP and/or CMAwith
its associated response on the design space. This becomes
even more relevant when striving to attain real-time release
testing (RTRT), where surrogates for therapeutic perfor-
mance are correlated not only with analytical release tests
but optimally to a specific process parameter(s) or material
attribute(s) that impacts that analytical response. It is in
these cases where mitigation of risk and optimal delivery
of product performance can be delivered because the
direct influence on quality can be measured. Additional
information on RTRT can be found in subsequent sections
of this paper.
Identifying Current Process Risk and Variability Using
Systematic, Multivariate Design of Experiments and Cross-Dis-
cipline Team. The risks associated with a product, whether
during development or commercial scale, are tied to the
amount of incoming variability caused by materials and pro-
cess conditions (i.e., parameters, equipment scale, means of
operation, etc.). Distinguishing critical parameters from those
variables whose impact is minimal or totally insubstantial is
the essence of pharmaceutical development. Cross-functional
teams composed of a wide array of disciplines (i.e., process
development experts, formulators, statisticians, analysts, tech-
nicians, etc.) provide a varied perspective on the important
formulation risks.
Traditionally, criticality evaluation has been performed
by varying one condition at a time. Using this methodology,
experiments are conducted by varying one parameter while
keeping all others constant (fixed) and then assessing the
response (impact). This manner at which variable perfor-
mance is studied one factor at a time (OFAT) is not necessarily
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how parameters behave during routine production. The
shortcoming of this methodology is that it fails to provide
the experimenter with an understanding of interactions
between variables. Oftentimes, these interactions go unno-
ticed and can result in synergistic affects when multiple
variables are allowed to vary collectively, thereby resulting
in a magnitude of effect that renders the initial parameter
range suboptimal.
In contrast, the design of experiment (DoE) approach
is designed to evaluate systematic variation of multiple
factors (i.e., variables) within the context of one experi-
mental design. DoEs can, thereby, be used to identify
criticality of variables and ultimately create mathematical
models of the process being examined aimed at predicting
process performance (23).
Once a relationship between a CPP and CQA is
demonstrated, the variable that demonstrated impact on
a CQA should be further evaluated with the goal of
understanding how much variability can be induced (i.e.,
how far the parameter range can be) in relation to other
parameters as they collectively deliver acceptable product
quality. Finding the technical edge of failure is not always
necessary when evaluating criticality factors, especially
when the range of the factor is unrealistically wide as it
will likely not be employed in production. Therefore,
when constructing a DoE, it is important to keep in mind
the level of desired variability induced in order to learn as
much as possible about a process within the given re-
source constraints.
The complex relationship between formulation design
factors, manufacturing unit operations, and their correspond-
ing quality attributes is shown in Fig. 1. It is the responsibility
of the development team to identify, and set control limits for,
the attributes that are found to be critical to the quality of the
product (22,23).
Assessment of Significance. Statistical significance results
when the factors of a study cause an impact to the identified
CQAs. It should be noted that although variables can have
statistical significance, the practical significance must also be
evaluated. If a sample size is large enough, variables will
undoubtedly demonstrate statistical significance. The scien-
tist must evaluate what practical meaning this effect has on
CQAs.
One way of accessing practical significance is to evaluate
the magnitude of effect the critical variable has on a given
CQA. For example, if particle size distribution is statistically
significant, it should only be deemed critical if the magnitude
of the affect is large enough to be of practical concern. This is
where establishing predetermined criteria for significance be-
comes valuable (as previously discussed).
Prior to the DoE and execution, the scientist should
clearly define how much variability in particle size distribution
is considered practically significant, in that the variability over
this predetermined range would likely have an impact on drug
product quality. While determination of statistical significance
may be generated from statistical packages (i.e., SAS, JMP,
MiniTab, etc.), practical significance determination should be
made with the CQAs and patient effects in mind. While a
variable may significantly impact an in-process attribute (i.e.,
particle size distribution, density, flow, etc.), the final CQAs
may not necessarily be impacted. This is commonly seen with
particle size distribution of granulation that may be impacted
by variability in upstream conditions (i.e., granulator speed,
time, etc.), but ultimately the overall manufacturing process
(such as milling, blending operations) is robust enough to
mitigate or eliminate these effects and no ultimate effect is
demonstrated on final product quality.
Combining Input Variables and Process Parameters that
Have Been Demonstrated to Provide Assurance of
Quality. Prior knowledge, proactive team-based risk assess-
ments, multivariate experiments, use of PATs (discussed in
later subsection), and continual improvements are used to
develop process understanding to a level necessary to estab-
lish a design space for a drug product or drug substance. The
design space reflects the product understanding as a multivar-
iate area where the impact on product quality is understood
and controlled based on the variability of critical processing
parameters and/or material attributes within a known range.
A distinction between a design space and proven acceptable
ranges (PARs) should be clearly made. PARs lack the capa-
bility to provide understanding of potential interactions
among other parameters throughout the drug product
manufacturing process. These interactions (either synergistic
or antagonistic) can potentially affect a process and may not
necessarily be determined if studied one at a time in a univar-
iate manner.
Essentially, the manufacturing process runs in a multivar-
iate environment (i.e., numerous factors are simultaneously in
operation). Therefore, the parameters of that process should
be studied in order to fully understand their effects on the
design space.
Defining an Appropriate Control Strategy
Mitigating Risk Through Maintenance of CPPs and Ad-
herence to Design Space to Ensure Product Quality. Once a
process is developed and transferred to commercial scale,
generally, the scope changes from inducing process vari-
ability in order to elicit an effect to monitoring the normal
variability in the process and establishing/maintaining pro-
cess control. Critical parameters that make up a design
space should be controlled and continually monitored for
trends and shifts that could occur over time in order to
avoid significant deviation which could ultimately impact
product CQAs. The design space is held within specifica-
tions via a control strategy, which is defined as “a planned
set of controls, derived from current product and process
understanding that ensures process performance and prod-
uct quality” (9).
The establishment of a control strategy is necessary to
ensure that the compliance of the drug product or drug sub-
stance processing parameters is delivered and that material
attributes are consistently met and remain within their
predefined settings. It is important to note that the control
strategy should be developed specifically for the individual
process that it monitors. A control strategy should include
appropriate elements that will provide monitoring and/or con-
trolling potential positioned at strategic junctures of a process
where criticality has been demonstrated. Typically, a control
strategy includes items such as additional in-process testing,
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use of PAT tools/probes, IT/software programs (i.e., feedback
loops and automated recipes), well-defined batch records,
specifications, etc. For example, if incoming raw material var-
iability has been demonstrated to be critical to a CQA [i.e.,
disintegrant, particle size distribution (PSD) impact on disso-
lution], a supplier change could alter the incoming PSD char-
acteristics that affect CQAs even though routine supplier
sourcing evaluation is followed and specifications met. It is
in this manner that true process monitoring is attained and, if
performed far enough upstream, intervention possible.
Means of Constant Process Observation Using Technology
and Science. Multivariate Data Analysis: As previously men-
tioned, criticality is determined by assessing the magnitude of
impact a variable (parameter or material attribute) has on a
response (CQA). Therefore, the relationship between the pa-
rameter and CQA needs to be understood. Multivariate data
analysis (MVDA) is a form of statistics that helps to understand
the relationships between variables, observations, and their rel-
evance to each other (using principal component analysis, PCA)
as well as relationships between variables and responses (using
partial least squares, PLS). When coupled with process knowl-
edge and criticality understanding, PLS and/or PCAmodels can
be used to construct multivariate statistical process control
(MSPC) charts in order to identify deviations from targeted
behavior. MVDA uses established algorithms to create linear
models comprising an approximation function and level of con-
comitant noise. MVDA models are designed to assess and
ensure (in near real-time) that the progression of a batch is
evolving within the defined design space during processing,
thereby ultimately yielding material meeting predefined critical
quality attributes. By this methodology, the process parameters
are summarized by a few critical variables (“scores”) instead of a
vast number of individual process parameters with limited
significance.
Generally, these variables are defined by production of a
series of target batches manufactured within normal operating
range (NOR) parameters. NOR conditions are generally
tighter than the encompassing design space and represent
the day-to-day parameter settings where slight variability is
allowed. Since the behavior of these batches is understood and
even desired, target batches are normally used to build the
reference model. Batches that were produced in other areas of
the design space, generally at greater extremes, are either
excluded from batch monitoring models or used to challenge
the model for sensitivity. Consequently, batch quality can be



























































































Fig. 1. Relationship between formulation design factors and CQAs
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their expected range can be visualized online in real time,
allowing for immediate attention and adjustment.
Process Analytical Technology. Process analytical tech-
nology (PAT) is defined as “a system for designing and con-
trolling manufacturing through timely measurements (i.e.
during processing) of critical quality and performance attri-
butes for raw and in-process materials and also processes with
the goal of ensuring final product quality”(13). PAT tools
include spectrographic equipment such as near-infrared
(NIR) and Raman, but can also include software enhance-
ments that lead to a greater understanding of process execu-
tion. Some examples include power consumption, ΔT
(difference in drying temperature used in wet granulation),
and the MSPC models described above. The one element
these examples of PAT have in common is their connection
to the dynamic process data of a specific parameter and
resulting data. These technologies allow for innovative devel-
opment means by providing fundamental understanding of
drug product processes.
Advances in technology have made available many tools
that provide effective means for acquiring information to
facilitate scientific understanding, continuous improvement
and development of risk-managed pharmaceutical develop-
ment, manufacture, and quality assurance. One of the most
common PATs is the utilization of multivariate tools for de-
sign, data acquisition, and analysis: For example, design of
experiments and multivariate data analysis seek to measure
the interactions between multiple process variables simulta-
neously. Interactions between process variables are the most
frequent attributable cause of process failures and are not
typically detected, and thus a major pitfall of the univariate
design. When used appropriately, multivariate tools enable
the identification and evaluation of product and process
variables that may be critical to product quality and per-
formance. These tools may also identify potential failure
modes and mechanisms and help quantify their effects on
product quality. Therefore, PAT is part of an overall
strategy of continuous improvement that enables continu-
ous learning through data collection and analysis over the
product life cycle.
PAT Process Controls, Controls Integration, and Informa-
tion Management. Process Controls and Model-Based Sys-
tems : In today ’s highly automated manufacturing
environment, parametric controls are a critical component of
the process control strategy and are fundamental to the pro-
cess information and knowledge base.
Multiple components in pharmaceutical manufacturing
machinery have elements of performance control, monitoring,
and measurement; however, only the relevant control ele-
ments that are influential to CQAs are typically included as
part of the process control strategy.
The evaluation of the equipment–product interaction is a
key element of risk management analysis. Analyzing equip-
ment–product interaction as part of the risk management tools
allows for the determination of what is important to measure
and control. ICH guideline Q9 provides risk analysis tools that
can be used in the determination of the equipment–product
interaction risk elements.
Typically, a pharmaceutical manufacturing process has
equipment components that fit the need for the type of control
design, either discrete, batch, continuous, or a combination of
them. Figure 2 shows a diagram of the equipment train of a
typical solids manufacturing process. Note that each piece of
equipment in the figure includes a list of the equipment para-
metric control elements that are commonly agreed as process
performance or safety controls. Filtering the quantum of para-
metric information into a critical parameter list requires the
analysis of the equipment–process interaction with respect to
available process knowledge and the criticality analysis on
product quality. The criticality analysis of the process para-
metric space results in a failure mode hypothesis that needs
empirical confirmation. The empirical confirmation of the
failure modes often requires experimental evaluation, partic-
ularly in a new product or process design; otherwise, historical
data or a combination of DOE and historical data shall lead to
the definition of the critical process parameters.
Upon DOE execution, the hypothetical failure modes
and their control definitions are either confirmed as critical
or regarded as noncritical for the product CQAs. The confor-
mance of the quality attributes satisfying the target product
profile expectation may then be defined in a design space
relevant to critical (equipment) process parameters (CPPs)
that become part of the equipment control strategy.
The availability of a multivariate DOE-based process
fingerprint shall be used in the establishment of process em-
pirical models that relate relevant CPPs to the product CQAs.
The initial goal for the use of the DOE data is to establish
control loops, or limits of manual adjustments by equipment
operators. In particular, when combined with CQA-surrogat-
ed process analytical technology (e.g., NIR, Raman, or fluo-
rescent spectroscopy), the empirical model can become a
process/product performance predictive model with real-time
release capabilities that could enable dynamic control strate-
gies. An expected subsequent improvement of the control
strategy should include the analysis of process relationships
to fundamental theoretical models that explain the observed
process performance with mathematical accuracy (e.g., first
principle and thermodynamic models, population balance
models, mass balance models, diffusion models, etc.). The
integration of the empirical data and the fundamental mathe-
matical modeling along with the in-process analytical technol-
ogy is a powerful tool that should become the ultimate goal of
the control strategy when possible. This is particularly true
when material quality attributes are well established and con-
trolled and previous knowledge regarding model systems rel-
evant to the pharmaceutical manufacturing process are
considered.
Controls Integration and Information Management: The
process control inputs, when defined relevant to the CQAs,
are part of the PAT toolset and contain statistically significant
predictive information that should be monitored and used as
part of the control strategy. Univariate parametric information
can be established as a first line of defense against process
variation that could be detrimental to product performance.
Charting techniques using statistically defined limits (e.g., run
charts, moving average, moving range, or Shewhart control
charts) can serve this purpose. Multivariate analysis of para-
metric data can also be important. Multiple regression analy-
sis, PCA, and partial least squares or projections to latent
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structures (PLS) are tools available for multivariable data
analysis. Charts of these data, either by score loading charts
(PCA or PLS), residuals analysis, control or run charts of the
product of the multivariable function, can provide adequate
control monitoring for the multivariable relationship, allowing
process parameter adjustment that is capable of restoring the
process balance in case of drift conditions. Examples of pro-
cesses that are multivariable in nature include wet granulation
process, fluid bed granulation, fluid bed drying, roller com-
paction, compression process, film coating process, etc.
The equipment controls system SCADA (Supervisory
Control and Data Acquisition) allows for data evaluation,
calculation, and display using graphical tools that should be
presented to the operator using a human–machine interface
(HMI). This information provides a means of alerting the
operator to deviations from the expected parametric perfor-
mance. Upon an observed deviation, there should be in place
deviation definitions and control policies (i.e., actions that
should be taken to reestablish the desired process outcome)
based on the defined CPPs and within the design space
established via DOEs. The control strategy can be based on
open loops, which require the operator to be trained and have
the necessary skills to perform a process correction. On the
other hand, a closed-loop control schema can be established to
automate the response to the drift condition and to restore the
process outcome independent of any operator action. The
control action can be a feedback action upon the control,
affecting the output of an upstream process step or equipment,
or a feed-forward action, for which the measure of the output
of the preceding step is used to define processing condi-
tions of downstream process steps. Similarly, the analysis of
intermediate material or final product property measure-
ments using CQA-surrogated PAT (e.g., NIR, Raman,
LIF, or other tests) should be considered in the control
loop strategy, either as open or close loops. Under the
scenario where the feedback or feed-forward control loop
is based on an analytical surrogate in-process test, it is
particularly important to ensure the adequacy of the mea-
surement system, including sample presentation (e.g., sam-
ple size, probe location, accuracy, and reproducibility of
measure), control loop response time, and define the
targeted control strategy (trajectory tracking, midpoint cor-
rection, or drift correction).
Life Cycle Management Through Proactive Process En-
hancement/Optimization. The established design space is re-
quired to be monitored throughout the life cycle of the
product. For example, annual product reviews (APRs) are con-
ducted on a yearly basis to assess the consistency of the quality
production. Based on the new information generated during
ongoing quality monitoring activities, any necessary improve-
ments and changes needed to address trending and/or process
optimization potential should be implemented as described in
local quality systems concerning change management.
Annual product reviews are industry standards for
assessing batch data over the yearly production activities.
CQA data are evaluated for shifts as well as variability both
over normal production as well as any post-process
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Fig. 2. PAT control elements of a typical solid dosage form
manufacturing process
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optimization implementation initiatives that may have taken
place. Statistical assessment of data can provide a more rep-
resentative account of CQAvariability. Statistical measures of
process quality capability, such as ANOVA, Cpk, and Ppk,
assess variability around a mean and can therefore quantify
the magnitude of variability of release data. DoE batches
would not be used to calculate process capability because of
the induced variability a DoE introduces to a process for the
purpose of impact assessment. Cpk is designed to evaluate
normal variability of a process (i.e., at set point or target
conditions). Although CQA impact assessment provided by
a DoE is beneficial from a CPP establishment perspective, the
batch results should not be used for Cpk calculation because
the inherent process variability cannot be assessed accurately.
When none of the DoE parameters studied have an impact on
a CQA, then all the DOE batches can be assessed collectively,
as noncritical parameters. Hence, only the batches that were
made with the same process conditions (i.e., target batches)
are included in the Cpk calculation.
Another component of life cycle management is the uti-
lization of continued process cerification (CPV) to proactively
monitor routine production. The goal of continued process
verification is to assure that the manufacturing process con-
tinuously remains within a predetermined state of control
during routine commercial manufacture. Through CPV, un-
planned deviations as well as trends in input variables, in-
process control (IPC) results, and final product quality are
detected and an assessment made regarding necessary im-
provements throughout the life cycle of the product.
A successful CPV program has systems in place which
have the ability to proactively identify potential issues before
they become critical. For example, statistically evaluating an-
alytical release data which may be within specification but
trending low or increasing in total variability can result in
the avoidance of an ultimate failure if the cause of variability
can be discovered and rectified prior to it reaching a signifi-
cant magnitude.
Statistical process control techniques and data collec-
tion plans may also assist with the evaluation process as
to the cause of variability. Statistical analysis of release
and in-process data coupled with in-depth process knowl-
edge obtained through risk assessment and criticality anal-
ysis can provide the means of identifying opportunities to
optimize the current process and/or identify areas where
enhanced detection mechanisms are needed to ultimately
improve end product quality.
Use of PAT in Supporting Post-approval Changes to IR
and MR Products. Quality risk management is a key part of
PAT implementations by identifying potential quality con-
cerns and implementing appropriate controls. The combina-
tion of risk management and PAT has allowed the ability not
only to identify potential quality concerns but also implement
ways to improve the likelihood of detection and/or control of
the product/process. This section discusses PAT applications,
how changes can be made to PAT applications, how they can
be added or removed from processes, and how they can be
used to support post-approval changes to an IR/MR product.
Rather than identifying specific controls required, examples
are provided and quality risk management is used to guide the
appropriate requirements for changes.
R&D Requirements for a PAT Application In Order
to Support Post-approval Changes: As part of product and
process development, PAT methods can be used to sup-
port process understanding and facilitate scale-up and
commercial site transfer. This information would be in-
cluded in the filing as part of the process justification.
The methods used for process understanding or design
space development may not be validated or required for
commercial manufacturing. Existence of these methods
and reference to them in the filing may facilitate using
the methods again for a site transfer, additional scale-up,
or other post-approval changes. It is expected that PAT
methods utilized in product/process development may sup-
port the post-approval change through inclusion of previ-
ous data and greater process understanding.
There are also scenarios where an online or at-line meth-
od is developed during development as a surrogate for a
traditional high-performance liquid chromatography (HPLC)
test . However, due to l imited number of batches
manufactured during development, the method would require
additional updates before full commercial implementation. As
defined by the PAT method maintenance strategy, after the
product is approved and commercial manufacturing begins,
data from commercial batches are used to update the PAT
method and demonstrate its capability to support the commer-
cial-scale process as intended. Assuming the defined outcomes
are achieved with regard to predefined acceptance criteria,
online/in-line might then become the primary commercial test
method.
It is possible to have an in-process PAT method in-
troduced to measure an attribute at an intermediate step
and eliminate the need for the measurement of that attri-
bute in the final product. In this case, it is not a direct
substitution but is a way of testing for a product attribute
at the appropriate manufacturing step and enables a feed-
forward or feedback control loop that could assist with
achieving consistent product quality by adjusting the ap-
propriate process parameter(s). PAT measurements at in-
termediate steps reduce product risk because they allow
for a process control and parameter adjustment to ensure
the final product meets a predefined quality specification.
Such a control scheme would also require sufficient com-
mercial-scale data prior to full implementation. This may
require, similar to what is mentioned above, completion of
method development by the development team and meth-
od inclusion in the filed documentation.
For the two cases above, predefined acceptance criteria
are needed prior to the filed submission and need to be agreed
upon by all accountable organizations or departments. In
addition, the methods proposed would be developed and
validated through collaboration between the development
and commercial organization. The expectation is that these
methods would be consistent with the sponsor’s validation
policy. In addition, discussion with the regulatory agency prior
to the filed submission is recommended to insure alignment of
expectations for the method validation, implementation, and
maintenance.
Support of Changes from Previously Filed PAT: PAT
methods are integral to continuous improvement and moni-
toring of a manufacturing process. It is expected that the PAT
method will itself evolve and require continual improvement.
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As such, the quality system for the PAT method should in-
clude a procedure for updating the method with respect to
increasing process understanding through greater process ex-
perience which captures variability associated with raw mate-
rials and non-product quality-related changes in the process.
The requirements for updating the PAT method will vary
depending upon the overall significance of the PAT method
to the process control strategy and the assessed impact of the
changes to method robustness. Simplified, the higher the crit-
icality of the PAT method to a product CQA, the greater the
expected level of detail for any changes to the PAT method.
This criticality is best determined by reviewing established risk
assessments. For example, a real-time release method, which
is considered a direct substitute for a traditional laboratory
release method, is a high-impact method, and changes to the
method would be expected to capture the performance attri-
butes critical to the CQA.
Complementary medium-impact methods (design space-
related methods that are not sole indicators of product qual-
ity) and low-impact methods (for process understanding and
development) would be expected to demonstrate perfor-
mance attributes aligned to the intended use of the method.
Some level of expectation for PATmethod evolution can be
set at the development stage of the PAT method based on
process and method development history. Ultimately, the PAT
methodmaintenance strategy needs to be specified as part of the
method’s quality systemdocumentation at the site. A descriptive
summary of themaintenance strategy should be included in filed
documentation to align expectations for method evolution with
agency guidance documents. In limited situations, where sup-
ported by a risk assessment, comparability protocols may be
specified in filed documentation. Although, due to the complex-
ity of comparability protocols, the preferred approach is to
include the strategy for anticipated update(s) as part of the
documented PAT method maintenance.
Post-approval of New PATApplications: The continuous
improvement and monitoring of a manufacturing process is
likely to provide the opportunity to implement or improve
PAT where it was previously not available or considered.
The determination of the regulatory filing category should
be based on the level of risk associated with the unit operation
or attribute for which PAT is being utilized combined with the
required filing category for associated changes. The following
examples are provided to demonstrate the different degrees of
risk and potential regulatory filing requirements.
Case 1 The current blending unit operation for a solid oral
dosage form includes blending of ingredients for a
set number of revolutions at a set speed. In order to
increase process understanding and gain additional
knowledge about the blending process, NIR mon-
itoring is added to the blending process to better
understand blend uniformity throughout the unit
operation. There is no change to themanufacturing
process as the blending unit operation process pa-
rameters remain unchanged. The addition of NIR
either maintains or reduces the current risk level
and would not require regulatory approval.
After gaining sufficient experience/data with NIR
monitoring of the blending step, it is determined
that controlling the completion of blending
through NIR rather than a set number of revolu-
tions ensures blend uniformity and a reduction in
blending time. Therefore, it is desired to change
the control of the blending step to utilize NIR.
Additional continuous process verification would
be added to ensure no change in the uniformity of
dosage units CQA; therefore, the risk level is
maintained or reduced. As a result of the change
to the manufacturing process, the change would
require regulatory approval (CBE/CBE30).
Case 2 The process of spraying drug substance onto a core
tablet is currently monitored using HPLC to deter-
mine the end-point prediction of the spray coating
process. In addition, assay testing is performed at
release for the finished product. A NIR method is
developed to monitor drug substance growth on the
core tablet, allowing rapid analysis and monitoring
for the completion of spray coating. The level of risk
is reduced due to the increased monitoring through
the coating end point, allowing for a more precise
end point determination. The change to the process
control would require regulatory approval (CBE/
CBE 30). After sufficient data are obtained using
NIR to determine end point through a PQS-ap-
proved continuous process plan, it is desired to use
NIR to replace finished product assay testing. The
risk level would be maintained or reduced, and the
change to specifications would require regulatory
approval through a CBE/CBE30.
In most situations, the implementation of PAT
will result in either a reduction of risk or main-
taining the current level, in which case prior ap-
proval (PAS) would not be required. This
assessment is in line with the current Guidance
for Industry Changes to an Approved NDA or
ANDA (edition date, April 2004), which states
“A change in methods or controls that provides
increased assurance that the drug substance or
drug product will have the characteristics of iden-
tity, strength, quality, purity, or potency that it
purports or is represented to possess” be submit-
ted as Changes Being Effected (CBE). The data
requirements for the CBE should include submis-
sion of the PAT methodology and its validation.
In addition, batch data demonstrating that the
product manufactured with the new or improved
controls continues to meet the existing specifica-
tions should be provided. The need for stability
data should be dependent upon the degree of
change to the process and the potential the
change has to impact the stability profile of the
product.
Removal of PAT Based on Practical and Scientific Con-
siderations: PAT developed and implemented during product
development stage serves as a key driver (or component) for
rationalization of the manufacturing processes, knowledge-
based production, and enhanced assurance of product quality
after product approval (or launch). Following knowledge ac-
cumulation during commercial production, PAT may be
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removed or reduced under certain circumstances based on
consideration of extent of product and process understanding,
nature and role of the PAT, complexity of the product and
process, availability, and life cycle cost of instrumentation. For
instance, the following scenarios may prompt evaluation of
possibly removing or replacing (or downsizing) PAT for com-
mercial production:
– When statistical process control demonstrates that removal
of the PAT does not result in a decrease in process capability.
– Change of manufacturing site where PAT transfer may be
challenging due to instrument availability, need for equipment
retrofit, method transfer, and cost.
– For products or processes that are controlled using a multi-
modal PAT, reduction of modality (e.g., to a single sensor) has
been proven to provide sufficient (or equivalent) process con-
trol. In general, reduction, replacement, or removal of PAT is
feasible (or can be considered) for a production operation that
is fully under control, and
demonstrates robustness of the manufacturing processes and
an understanding of the interplays between the process in-
volved and raw material properties, scale, and type of equip-
ment, etc.
shows consistent correlation between parameters of in-line or
online analytical systems (e.g., NIR) and a non-PAT in-process
control (e.g., number of revolution of a blending operation)
within its design space.
When removing PAT, caution should be exercised for a
complex manufacturing process and/or drug product, such as
modified-release or amorphous solid dispersions, or where
the replacement process control is purely empirical in na-
ture (e.g., a combination of mixing time and liquid volume
for determining the end point of a wet granulation pro-
cess). Risk assessments should be revisited and updated to
justify any reductions, replacements, or removal of PAT.
Use of PAT in Supporting Post-approval Changes to IR
and MR Products: The principles for the SUPAC QbD ap-
proach are based on product-specific risk assessment of chang-
es which may impact approved design spaces within the
framework of the approved control strategy to ensure consis-
tent product quality and performance. The changes and re-
quirements are less prescriptive compared to the SUPAC IR/
MR approach, although they require a detailed and docu-
mented understanding of the formulation and process with a
focus on continuous learning and improvement. These general
principles for application of the QbD approach include no re-
quirements for regulatory notification for changes within ap-
proved design spaces. Under this latter scenario, all
documentation to support the proposed changes would be
managed through the PQS and be available for submission
or review when requested. This documentation includes:
changes to batch records, risk assessments with technical
justifications to support process qualification testing, extend-
ed dissolution/bioequivalence requirements, stability and con-
tinuous verification plans. Use of the proposed QbD
approach incorporating specific PAT in the control strategy
is illustrated by several examples in Table I below for com-
parison to the traditional SUPAC IR/MR approach. The
examples are general in nature, but specific scenarios under
the general cases were developed in order to further dem-
onstrate the QbD principles.
Table I provides a comparison of the current SUPAC IR/
MR requirements and the proposed requirements that result
when an IR or MR product has been developed using QbD.
Included in the table are the following SUPAC change control
concepts:




– Application of compendial release documentation
– Stability documentation
– Dissolution documentation
– In vivo bioequivalence documentation
The following examples provide further detail on the
information found in Table I.
Example 1 SUPAC IR Level 1—Batch size change <10×
biobatch (final blend size)
Current SUPAC Requirements: Annual notification with up-
dated batch records, one lot on long-term stability; release via
compendial/application specifications
Proposed QbD Approach: No notification if within approved
blending design spaces or uniformity is controlled with in-line
NIR; documentation managed internally through PQS, includ-
ing documented risk assessment and justification for stability,
extended testing beyond release, and continuous process ver-
ification plan
Rationale: No stability requirement since no expected change
to stability indicating CQA; plan to monitor stability indicat-
ing CQA (moisture) and content uniformity using NIR (if
applicable). No additional dissolution testing required based
on risk assessment. Default to SUPAC requirements if no
adequate technical justification can be developed, for exam-
ple, no stability indicating CQA can be documented in risk
assessment
Example 2 SUPAC IR Level 2—Batch size change >10×
biobatch (final blend size)
Current SUPAC Requirements: Changes being effected sup-
plement with updated batch records; one batch with 3 months’
accelerated stability data and one batch on long-term stability;
multipoint dissolution profile comparison in the application/
compendial medium versus pre-change/reference lot
Proposed QbD Approach: No notification if within approved
blending design spaces or uniformity is controlled with scale-
independent approach such as in-line NIR; documentation
managed internally through PQS, including documented risk
assessment and justification for stability, extended testing be-
yond release, and continuous process verification plan
Rationale: No stability requirement since no expected change
to stability indicating CQA; plan to monitor stability indicat-
ing CQA (e.g., moisture) and content uniformity using NIR.
No additional dissolution testing required above release with
approved clinically relevant dissolution method and specifica-
tions or if process remains within the blending design space.
Default to SUPAC requirements if no adequate technical
justification can be developed, for example, no approved
blending design spaces or scale-independent control strategy
can be documented in risk assessment
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Example 3 SUPAC IR Level 2—Change in granulation
process, e.g., change in roller compaction roll
pressure set point outside of filed/validated
range
Current SUPAC Requirements: Changes being effected sup-
plement with updated batch records; one batch on long-term
stability; multipoint dissolution profile comparison in the ap-
plication/compendial medium versus pre-change/reference lot
Proposed QbD Approach: No notification if within approved
roller compaction design spaces or if ribbon attributes con-
trolled within approved in-process controls, for example, using
a validated and approved at-line or online ribbon density PAT
measurement technique, e.g., NIR or GeoPyc; SUPAC docu-
mentation managed internally through PQS, including docu-
mented risk assessment and justification for stability, extended
testing beyond release, and continuous process verification
plan
Rationale: No stability requirement since no expected change
to stability indicating CQAs or technical justification of no
stability impact with change in ribbon density within design
space; plan to monitor downstream controls (e.g., tablet hard-
ness and weight uniformity) and ribbon density within design
space in addition to the continuous process verification plan
for monitoring CQAs. No additional dissolution testing re-
quired above release with approved clinically relevant disso-
lution method and specifications or if process remains within
the roller compaction design space. Default to SUPAC re-
quirements if no adequate technical justification can be
developed, e.g., outside of approved roller compaction design
spaces or no ribbon attribute-based control can be document-
ed in risk assessment
Example 4 SUPAC MR Level 2—Change in coating
quantity of rate controlling excipient (ER
membrane coating) between 5% and 10%
(w/w) of the tablet mass
Current SUPAC Requirements: Prior approval supplement (all
information including accelerated stability data) and updated
executed batch records; stability for non-narrow therapeutic
range drugs: one batch with 3 months’ accelerated stability
data reported in prior approval supplement and long-term
stability data of first production batch reported in annual
report; extended-release dissolution requirement: in addi-
tion to application compendial release requirements,
multipoint dissolution profiles should be obtained in three
other media, for example, in water, 0.1 N HCl, and USP
buffer media at pH 4.5 and 6.8 for the changed drug
product and the biobatch or marketed batch (unchanged
drug product) using appropriate statistical comparison,
e.g., f2 similarity
Current QbD Approach: No notification if change is within
membrane quantity design spaces or if quantity is con-
trolled within approved in-process controls using a validat-
ed and approved at-line or online PAT measurement
technique, for example, NIR, Raman spectroscopic tech-
niques; documentation managed internally through PQS,
including documented risk assessment and justification for
Table I. Use of PAT in Supporting Post-approval Changes
Change control element Current SUPAC IR/MR Proposed QbD approach
Change control
management
Highly specified in guidance
documents for most elements
Follow principles outlined in ICH Q10 for PQS.
Types of changes Highly prescriptive, independent
of product sensitivities
Product specific related to changes impacting design space
and control strategy as outlined in ICH Q8(R2) and ICH Q11
Risk evaluation Highly prescriptive based on
level 1, 2, and 3 changes
Customized based on principles outlined in ICH Q9 for
QRM. Example, assess level of risk such as FMEA tool
based on prior knowledge and science with technical justification.
Filing documentation Highly prescriptive based
on level of change
No filing documentation required for changes within design
space. Changes outside of design space would follow current
regulatory requirements. May need to consider changes to
any control strategy element from QRM approach
Manufacturing
documentation
Specified for most changes Managed through PQS
Application of compendial
release documentation
Specified for most changes Managed through PQS. May need to consider additional extended
testing and validation requirements such as continuous process
verification based on QRM approach
Stability documentation Highly prescriptive based
on level of change
Customized based on risk assessment and product sensitivities.
May need to consider the impact of any change to a control
strategy element that could impact stability-indicating CQAs
Dissolution documentation Highly prescriptive based
on level of change
Customized based on risk assessment and product performance
sensitivities
May need to consider the impact of any change to a control




on level of change
Customized based on risk assessment and product performance
sensitivities. May need to consider the impact of any change
to a control strategy element that could impact clinically
relevant CQAs
PAT process analytical technologies, QBD quality by design, CQA critical quality attributes, QRM quality risk management
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stability, extended testing beyond release, and continuous
process verification plan
Rationale: No stability requirement since no expected change
to stability indicating CQA or technical justification of no
stability impact with changes in coating quantity within the
approved design space; plan to monitor critical coating param-
eters and film thickness/quantity within design space in addi-
tion to the continuous process verification plan for monitoring
CQAs. No additional dissolution testing required above re-
lease with approved clinically relevant dissolution method and
specifications or if process remains within the coating quantity
design space. Default to SUPAC requirements if no adequate
technical justification can be developed, for example, outside
of approved coating quantity design spaces or insufficient
coating quantity in-process control with clinically relevant
dissolution assessment that can be documented in risk
assessment
Example 5 SUPAC MR Level 3—Change in site of
manufacture
Current SUPAC Requirements: Prior approval supplement (all
information including accelerated stability data) and updated
executed batch records; stability with significant body of in-
formation not available: three batches with 3 months’ acceler-
ated stability data reported in prior approval supplement and
long-term stability data of first three production batches re-
ported in annual report; extended-release dissolution require-
ment: in addition to application compendial release
requirements, multipoint dissolution profile for the changed
drug product and the biobatch or marketed batch (unchanged
drug product) using appropriate statistical comparison, e.g., f2
similarity. Bioequivalence documentation: a single-dose bio-
equivalence study. The bioequivalence study may be waived
in the presence of an established IVIVC.
Proposed QbD Approach: Notify via Changes Being Effected
Supplement (CBE-30) with no changes to approved design
spaces and control strategy compared to the original approved
site; documentation managed internally through PQS, includ-
ing documented risk assessment and justification for stability,
extended testing beyond release, and continuous process ver-
ification plan. Emphasis should be on demonstrating equiva-
lent quality and performance in the supplement through direct
confirmation of design spaces at the new site, with additional
emphasis on demonstrating equivalent in-process controls and
attributes from the approved in-process tests using the at-line
or in-line PAT tests (if applicable).
Rationale: Consider the change in location of an extended-
release coating process to another site. All design spaces were
confirmed at the new site without changes to the approved
control strategy. From the risk assessment, it was determined
that there was no stability CQAs for the drug product that
could be monitored or which could be predicted. Therefore,
the first three process qualification lots are put on accelerated
stability and 3-month data included in the supplement. How-
ever, it was demonstrated that control of the controlled-re-
lease membrane was found to be equivalent via the approved
in-process PAT methods for the controlled-release attribute,
film thickness, which was previously shown in development to
be clinically relevant and which correlated with dissolution.
Consequently, there were no demonstrated changes to the
rate-controlling step and, therefore, no bioequivalence study
is required. No additional dissolution testing required above
release with approved clinically relevant dissolution method
and specifications or if process remains within all design
spaces. The continuous verification plan would monitor CQAs
as well as any in-process controls for the rate-controlling step.
Default to SUPAC requirements if all design spaces cannot be
confirmed without changes to the approved control strategy
from the original site.
Improvement in the Control and Characterization of APIs
(Analysis and Recommendations Based on Post-approval
Change Guidance Documents)
Evolution of Drug Substance Control Strategy. Before the
introduction of QbD concepts to pharmaceutical manufactur-
ing, the approach to quality control was to test the drug
substance to certain predetermined standards. Product quality
was assured by ensuring conformance to current good
manufacturing practices (GMPs) and end product testing. It
needs to be noted that these principles still remain the corner-
stone to the quality standards of today and continue to be
valid.
ICH has developed guidelines that seek to redefine the
traditional approach to ensuring quality by introducing qual-
ity-by-design principles. Readers are encouraged to familiar-
ize themselves with the principles of ICH Q8, Q9, Q10, and
Q11 in order to gain the needed perspective on development
practices.
Drug Substance Quality as a Function of Drug
Product. Drug product quality and performance consider-
ations are very important to consider in determining the
intended quality of drug substance. QTPPs and CQAs of
the drug product (as defined in ICH Q8) and previous
experience from related products can be helpful in iden-
tifying potential CQAs of the drug substance. Quality risk
management (QRM; ICH Q9) and knowledge manage-
ment (ICH Q10) can be used to facilitate manufacturing
process development and design of the manufacturing
process.
Quality by Design: Beginning with the End in Mind…and
Working Backwards. QbD principles ensure quality through
the entire product life cycle and encompass manufacturing
changes both pre- and post-approval. API processes devel-
oped through product and process knowledge can result in
well-defined and understood material attributes, quality attri-
butes, process parameters, and control strategies that assure
product quality throughout the product life cycle.
– Less reliance on end product testing to assure quality
– Efficient use of supply chain infrastructure, thereby enhanc-
ing one’s ability to expeditiously respond to changes in prod-
uct demand
– Better innovation and continuous improvement
– Opportunities for post-approval regulatory flexibility by
demonstration of product quality within the proposed design
space
The ICHQ11 guidance document (12) describes two different
approaches to developing a drug substance: “traditional” and
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“enhanced.” A sponsor may choose either approach to drug sub-
stance development or a combination of both.
In the “traditional” approach, set points and operating
ranges for process parameters are defined and the drug sub-
stance control strategy is based on the demonstration of pro-
cess reproducibility and testing to meet established acceptance
criteria. NORs and PARs for process parameters may be
established under the traditional approach by use of univari-
ate design/analysis of process attributes.
In the “enhanced” approach, risk management principles
and scientific knowledge are used more extensively to identify
and understand process parameters and unit operations that
impact the CQAs and develop appropriate control strategies
that are applicable over the life cycle of the drug substance,
which may include the establishment of a “design space.”
Design space is submitted to the FDA as part of the
marketing application and subject to approval by the agency.
In principle, any movement within the approved design space
does not constitute a change and, hence, does not need to be
reported to the FDA. Conversely, changes that are outside of
the approved design space have to be submitted to the FDA
for review and approval before the product is distributed.
Regulatory flexibility is realized by ensuring that the process
operates within the design space, as approved in the original
application. The QbD approach enunciates six principal steps
in development that should be done in the following order:
– Develop the quality target product profile
– Identify critical quality attributes
– Perform a risk assessment
– Develop design space
– Define control strategy
– Continuous improvement/life cycle management
A well-understood manufacturing process/product perfor-
mance with a robust control strategy and a nimble manufacturing
and supply chain infrastructure that can accommodate varying
product demand during development through post-approval
while at the same time ensuring lean, just-in-time manufacturing
are among the desired attributes of a successful product.
Factors Impacting Drug Substance Quality—CPPs and
CQAs. A CQA for the drug substance is a physical, chemical,
biological, or microbiological property or characteristic that
should be within an appropriate limit, range, or distribution to
ensure the desired product quality. Drug substance CQAs
typically include attributes that affect the identity, purity, bio-
logical activity, and stability. Potential CQAs for the drug
substance include chemical purity, enantiomeric purity (if ap-
plicable), impurities including genotoxic impurities, polymor-
phic form, particle size, and other attributes that have a direct
relationship to the manufacturability, quality, and perfor-
mance of the drug product. The list of CQAs can be modified
as the knowledge of the drug substance and the manufacturing
process increase during development
There are many factors that impact the quality of the drug
substance and hence need to be part of the overall control
strategy, including but not limited to
– Manufacturing site
– Material attributes (e.g., of starting materials, raw materials,
reagents, solvents, intermediates, process aids, etc.).
– Manufacturing process including in-process controls and
process parameters (e.g., route of synthesis, order of addition
of reagents, etc.).
– Analytical methodologies used in the testing of materials
(raw materials, starting materials, intermediates, solvents,
etc.) and final drug substance
– Drug substance specification (release testing)
– Drug substance container-closure system
Assessment of CQAs and Continuum of Criticality
Throughout the API Product Life Cycle: Scientific knowl-
edge based on development experience and first principles
and QRM techniques are used to reach a decision on the
CPPs and CQAs for a given drug substance manufacturing
process. In this context, it is important to understand the
relationship between risk and criticality of quality attributes
and process parameters (10). The criticality of a quality
attribute is primarily based upon the severity of harm and
does not change as a result of risk management. Criticality of
a process parameter is linked to the parameter’s effect on
any critical quality attribute. It is based on the probability of
occurrence and detectability and therefore can change as a
result of risk management.
The drug substance control strategy can be determined
by either a traditional approach based on material specifica-
tions and process parameter ranges or using an enhanced
approach via risk management and scientific knowledge. The
iterative nature of product and process development requires
that attention is given as early as possible in development, to
refine the QTPP, the initial list of potential CQAs, and to
move toward the proposed list of CQAs and establishing
acceptance criteria for the critical material attributes. An
effective control strategy for the drug substance that links
changes in drug substance attributes to finished product
safety and efficacy ensures that the API manufacturing
process consistently produces a product that meets those
QTPP and CQAs throughout its life cycle, as shown in
Fig. 3 (24).
Design space is typically developed at a small scale and
hence has to be supplemented by an effective control strategy
to manage the risk after development and implementation.
Development of the design space greatly relies on
existing body of knowledge on the drug substance and its
manufacturing process. The level of variability present in the
historical data will influence the ability to develop a design
space, and additional studies should be considered in such
cases. A design space may also be determined per unit oper-
ation (e.g., crystallization, reaction, distillation, filtration, etc.)
or a combination of selected unit operations. The unit opera-
tions included in such a design space should be selected based
on their impact on the drug substance CQAs.
Drug Substance Control Strategy: A control strategy is a
planned set of controls, derived from current product and
process understanding that assures process performance and
product quality (9). The control strategy for API can include
any or all of the following:
– Controls on material attributes
– Manufacturing process controls including unit operations
(order of addition of reagents, rate of addition, temperature,
agitation speed, etc.)
– In-process controls
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– Final release testing of the drug substance
The control strategy should ensure that each of the drug
substance CQAs is within the appropriate range, limit, or
distribution to assure quality of the drug substance that meets
all the performance objectives for the drug product. The drug
substance specification is only one part of a total control
strategy.
The control strategy is typically developed during the
clinical research stage of development and undergoes fur-
ther refinement as further manufacturing experience is
gained during clinical development through commerciali-
zation. It should be continually evaluated as development
progresses and/or when changes are made. The complexity
of the process; changes in scale (scale-up or scale-down);
differences in the manufacturing process including equip-
ment, facilities, sites, etc.; and change in raw material
attributes due to supplier changes, etc., are some impor-
tant considerations in ongoing evaluations of the drug
substance control strategy.
Advancements in Instruments and Methods Used in Control and
C h a r a c t e r i z a t i o n o f A c t i v e P h a r m a c e u t i c a l
Ingredients—PAT. PAT is a system for designing, analyzing,
and controlling manufacturing outputs through timely measure-
ments (i.e., during processing) of critical quality and perfor-
mance attributes of raw and in-process materials and processes
with the goal of ensuring final product quality (25,26). Rapid
advances in PAT tools have brought about paradigm shifts in
traditional methods and approaches to ensuring drug substance
quality.
The underlying principle behind PAT is the belief that
quality cannot be tested into the products; it should be built-in
or should be by design.
Drug Substance Process Understanding: Structured prod-
uct and process development on a small scale, using experi-
mental design and use of online or in-line instruments to
collect data in real time, can provide increased insight and
understanding for process development, optimization, scale-
up, technology transfer, and control. Process understanding
then continues in the production phase when other variables
(e.g., environmental and supplier changes) may possibly be
encountered. A manufacturing process is generally considered
well understood when
– All critical sources of variability are identified and
explained.
– The variability is managed by the process controls.
– API product quality attributes can be accurately and reli-
ably predicted over the design space established for materials
used, process parameters, manufacturing, environmental, and
other conditions.
Focus on process understanding can reduce the burden
for re-validation of systems by providing more options for
justifying and qualifying systems intended to monitor and
control the biological, physical, and/or chemical attributes of
materials and processes.
Methods and Tools: The last three decades have seen
significant progress with respect to methods and tools for
chemical attributes (e.g., identity and purity); however,
methods and tools to characterize certain physical and
mechanical attributes of pharmaceutical ingredients are
not necessarily well understood. As a consequence, inherent,
undetected variability of rawmaterials may bemanifested in the
final product.
Establishing effective processes for managing physical
attributes of raw and in-process materials requires a funda-
mental understanding of attributes that are critical to product
quality. Such attributes (e.g., particle size and shape variations
within a sample) of raw and in-process materials may pose
significant challenges because of inherent complexities related
to collecting representative samples.
Many pharmaceutical processes are based on time-de-
fined end points based on prior experience and knowledge
derived from process development. However, differences in
material attributes and other process conditions can result in
variability in API quality attributes that may not necessarily
correlate well with the aforementioned time-defined end
points. Use of PAT tools and principles can provide valuable,
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Fig. 3. Assessment of the impact of API CQAs on product quality
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real-time information on process performance and physical,
chemical, and biological attributes.
Improvements in the Control and Characterization of Critical
Excipients. For many years, the impact of excipients, or more
specifically the impact of variability in excipient properties, on
the CQAs of pharmaceutical products was treated as an un-
controlled, poorly understood variable input to the
manufacturing process. Testing of excipients has traditionally
focused on pharmacopeial requirements, which are more
identity- and purity-centric rather than functionality-oriented.
Manufacturing difficulties encountered by various companies
over the last 20+years, especially in compression and lubrica-
tion steps, raised the need to characterize the potential impact
of excipient variability (i.e., CMA) on CQAs. USP Excipient
performance Chapter <1059> has now been established to
address additional functional tests (particle size, size distribu-
tion, surface area, etc.) which are not covered by individual
excipient monographs. The European Pharmacopeial Com-
mission has taken a similar (yet different) approach by adding
functionally related characteristics (FRCs) to Ph. Eur.
monographs.
Quality-related developments such as GMPs for the
twenty-first century (28), the advent of PAT, improved analyt-
ical methodology, and the various statistical tools readily avail-
able enable better quantification of the impact of variability in
excipient lots and parameters on the CQAs. The outcome is
that the product is better quantified and, consequently, its risk
better managed. Thus, the result will be a more robust
manufacturing process and more consistent quality of the
finished product.
Critical Excipients Based on Function: Excipients are
selected to serve particular functions in a product and, there-
fore, bear the potential to impact either CQA (such as the
release rate, uniformity, stability) and/or manufacturability of
the drug product. Consequently, any assessment of whether an
excipient is critical or not needs to be performed to address its
potential impact on either CQA of the product or associated
manufacturing process. The identification of which CMAs
have the most effect on the CQAs of the drug product should
be a risk-based process, in line with ICH Q8(R2). This can be
part of a larger study including process parameters with the
goal of defining a design space, but the use of a formal design
space strategy is not a requirement for assessing the potential
impact of material attributes so long as it is done in a system-
atic manner.
The proposed standard should be a systematic assessment
approach starting with a high-level risk assessment, followed
by experimental evaluation, and, finally, identification of
PARs for CMAs, as outlined below.
– A risk assessment
– Experimental evaluation
– Determination of PAR for critical material attributes
– Confirmation studies and/or real-life production experience
Risk Assessment: It is recommended that the evaluation
process begin with an initial wide-scope risk assessment. It
should be recognized that every component of the unit for-
mula that can be assigned a function is important. All
components have some inherent variability. Any component
variability that causes a quality attribute to go outside of
acceptable ranges is demonstrating a CQA that needs to be
carefully defined and controlled. One option for documenting
this assessment is via a cause-and-effect matrix. The output of
the risk assessment will be a ranking of the potential of each of
the excipient material attributes to impact each CQA of the
product. It is recommended that this ranking be used as the
basis for any experimental evaluation that is conducted.
Experimental Evaluation: The purpose of the experimen-
tal evaluation is to characterize the impact of known material
attribute variability on the CQA of the product and
manufacturing process. As mentioned previously, this could
be combined with an evaluation of composition and process
parameters or performed separately. The risk assessment pro-
vides a starting point for determining what should be evaluat-
ed, with the focus on the material attributes ranked as having
the highest potential to impact the product. There may be
practical reasons why some of the material attributes which
ranked high cannot be evaluated. For example, all of the lots
of material available may have a material attribute within a
narrow range even though the allowable range of variation
may be broader. Taking practical considerations into account,
it is recommended that studies be conducted, preferably using
a statistical experimental design, in order to identify the im-
pact of variation in the material attributes. The ranges evalu-
ated for material attributes should take into account the range
typically achieved by the manufacturer and how that com-
pares to the excipient manufacturer’s specification, and the
manufacturer’s process capability if that is known. For exam-
ple, in the evaluation of controlled-release matrix formers, it is
typical to include viscosity (molecular weight) as a parameter
in the design. Given the improvement in computation tools, it
is also possible to conduct evaluation using modeling tech-
niques, thereby significantly reducing experimental workload.
Determination of PAR for Critical Material Attributes:
The appropriate use of statistical experimental designs to
assess the impact of material attributes on the CQA of the
product, ideally at the same time as assessing processing var-
iables, will result in an understanding of the ranges for these
material attributes which will give an acceptable product. This
will form part of the design space for the product. In many
cases, the design space will be complex and reflect the inter-
active relationship between variability in material attributes
and the variables in the manufacturing process. It is common
for sponsors to further implement a tighter NOR based on the
established design space in order to enhance process
capability.
Many excipients are used to manufacture multiple prod-
ucts. Therefore, the specifications used to identify their fit for
purpose need to be constructed based on the complete range
of products for which an excipient is used. One option to
control excipients for a particular product, when needed, is
by the means of establishing additional critical material attri-
butes under a separate internal product code specific to that
product.
Confirmation Studies and Real-Life Production Experi-
ence: Ultimately, designation of critical material attributes and
process parameters will either be proven or disproven through
additional confirmation studies involving multi-sourced
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excipients. Vendor-to-vendor excipient differences will be
highlighted, if any, through excipient qualification studies
and, when warranted, confirmation batches of the drug prod-
uct. As routine production commences using more excipient
batches, real-life data can be evaluated to confirm selected
NOR or revised accordingly in the spirit of continued process
verification, as outlined in the FDA guidance on process
validation issued in January 2011 (27,28).
Additional Considerations Other Than Functionality: Al-
though excipients are selected based on their intended function-
ality, many times, minor impurities associated with excipients
bring unanticipated challenges to a drug product’s long-term
performance. It is common knowledge that peroxides, anhy-
drides, and other organic solvents associated with excipients
can interact with the API, forming degradation products, there-
by causing stability concerns. These impurities and residual
solvents can be either inherent from the excipient source (i.e.,
natural products), formed during the excipient manufacturing
process, or liberated from the excipient during the drug product
manufacturing process. Regardless, vigilance should be paid to
the evaluation of such excipient impurities or residual solvents
as part of stressed manufacturing process studies (e.g., known
susceptibility at extremes of temperature or force) or stressed
stability conditions. If needed, control of the levels of these
impurities or residual solvents would warrant incoming specifi-
cations to assure long-term drug product performance.
Role of IVIVC in the Development and Scale-Up of IR and
MR Products
The term in vitro–in vivo correlation (IVIVC) refers to
the establishment of a rational relationship between an in vivo
parameter derived from drug plasma concentrations produced
by a dosage form (e.g., Cmax or AUC) and an in vitro charac-
teristic of the same dosage form (e.g., dissolution) (29). The
quantitative relationship between the in vivo and in vitro
properties is an IVIVC. The most important utilization of an
IVIVC is that of predictability of the clinical performance of a
dosage form based on dissolution data. In some cases, the
actual drug plasma concentration profile may be predicted
from in vitro dissolution data. If prediction cannot be accom-
plished, it does not mean that the in vitromethod is necessarily
invalid. If a relationship cannot be established between the
dissolution and bioavailability of a dosage form, an in vitro–-
in vivo “relationship” or “association” can still be of great
value to a formulation group when the dissolution method is
predictive of in vivo behavior.
Historically, IVIVC analysis has been more successful for
modified-release products than for immediate-release dosage
forms. This difference in success probably reflects the appli-
cation of specific data analysis techniques and interpretation
that require dissolution rate-limited drug absorption and that
the release of drug from extended-release dosage forms can
be significantly affected by the drug product formulation.
Numerous attempts have been made to correlate various
in vivo PK parameters with in vitro dissolution data. Single-
point correlations show that increasing or decreasing the
in vitro dissolution rate of a modified-release dosage form
can result in a corresponding directional change in the
in vivo performance of the product (e.g., Cmax or AUC in-
crease with an increase in the dissolution rate). However, such
single-point correlations do not revealmuch information regard-
ing the overall plasma concentration–time profile. Thus, corre-
lation methods that utilize all available plasma drug
concentration and in vitro data are preferred. There are three
correlation levels available that utilize dissolution and plasma
data, but there are significant differences in the quality of the
correlation obtained with each procedure. These methods or
correlation levels are outlined below in terms of the advantages
of each along with its potential utility as a predictive tool.
Three correlation levels have been defined and catego-
rized in descending order of the quality of predictability (29–
31). The concept of correlation level is based upon the ability
of the correlation to reflect the entire plasma drug concentra-
tion–time curve that will result from administration of the
given dosage form. It also relates the entire in vitro dissolution
curve to the entire plasma concentration–time profile; the
strength of this relationship defines its inherent predictability.
Level A Correlation
Level A correlation is the highest category of correlation. It
represents a point-to-point relationship between the in vivo input
rate (absorption rate) and in vitro dissolution of the drug. For a
level A correlation, a product’s in vitro dissolution curve is com-
pared to its in vivo input curve. This in vivo curve, produced by
deconvolution of the plasma profile, may be accomplished using
mass balance model-dependent techniques, such as the Wagner–
Nelson or Loo–Riegelman methods, or by model-independent
mathematical deconvolution. Ideally (though not an absolute
requirement), the in vitro and in vivo curves are superimposable
or may be made to be superimposed by the use of a constant
offset value of the timescale, and therefore the equations describ-
ing each curve are the same. Such a relationship is most often
found with those modified-release dosage systems that demon-
strate an in vitro release rate that is independent of the dissolution
media and stirring speeds employed in a dissolution apparatus.
The advantages of a level A correlation are as follows:
– A point-to-point correlation utilizes every plasma level and
dissolution point collected at different time intervals and, thus,
reflects the complete plasma level curve. With a level A correla-
tion, the in vitro dissolution curve may serve as a surrogate for
in vivo performance. Therefore, changes in manufacturing site,
method of manufacture, raw materials, minor formulation modi-
fications, and even product strength using the same formulation
can be justified without the need for additional bioavailability/
bioequivalence studies so long as the product’s dissolution profile
is unaffected.
– The in vitro dissolution method is validated as a quality
control procedure that is meaningful and predictive of a dos-
age form’s in vivo performance.
– The extremes of the in vitro quality control standards for a
product (e.g., TPP) can be justified either by convolution
(simulating the plasma level profile from the dissolution
curve) or by a deconvolution procedure (utilizing the upper
and lower confidence interval limits).
Level B Correlation
This correlation utilizes the principles of statistical mo-
ment analysis. The mean in vitro dissolution time is compared
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to either the mean residence time or the mean in vivo disso-
lution time. As with a level A correlation, level B utilizes all of
the in vitro and in vivo data, but is not a point-to-point corre-
lation. It does not correlate the actual in vivo plasma profiles,
but rather a parameter that results from statistical moment
analysis of the plasma profile such as mean residence time.
Because there are a number of different plasma profiles
(shapes) that will produce similar mean residence time values,
it is not possible to rely upon a level B correlation alone to
predict a plasma profile from in vitro dissolution data. Also,
in vitro data from a level B correlation cannot be used to
justify the extremes of a product’s quality control standards.
Level C Correlation
This category relates one dissolution time point (t50%, t90%,
etc.) to a single pharmacokinetic parameter such as AUC,Cmax, or
Tmax. Similar to a level B correlation, a level C correlation repre-
sents a single-point correlation and does not reflect the complete
shape of the plasma profile which best defines the performance of
modified-release products. Since this type of correlation is not
predictive of actual in vivo product performance, it is generally
only useful as a guide in formulation development or as a produc-
tion quality control procedure. Because of its obvious limitations, a
level C correlation has limited usefulness in predicting in vivo drug
performance and is subject to the same caveats as a level B corre-
lation in its ability to support product and site changes as well as
justification of quality control standard extremes.
Correlation for IR Dosage Forms
Since the mechanisms for release of drug from immedi-
ate-release dosage forms are simpler than that for modified-
release dosage forms (which are more complex and variable),
one might expect that an IVIVC would be easier to develop
with IR formulations. However, most of the correlation efforts
to date with immediate-release dosage forms have been based
on the correlation level C approach, although there also have
been efforts employing statistical moment theory (level B).
Although it is conceivable that the same level A correlation
approach may be utilized with immediate-release dosage
forms, until data have been gathered to support this concept,
levels B and C are the best approaches that can be recom-
mended with these dosage forms.
General Considerations for Developing IVIVCs
The following concepts were adopted from the FDA
IVIVC Guidance (29). General considerations for developing
and evaluating a level A in vitro–in vivo correlation include
– Human data should be used for regulatory consideration.
– IVIVCs should utilize sufficient subjects (a statistically
powered sample) to adequately characterize the drug product
performance. Crossover studies are preferred, but appropri-
ately powered parallel studies may be acceptable.
– It is expected that, in order to develop a correlation be-
tween a drug product’s PK and its dissolution, several formu-
lations with different release rates may need to be evaluated.
These formulations should have at least a 10% difference in
dissolution rates.
– The IVIVC should be demonstrated consistently, with two
or more formulations with different release rates that result in
corresponding differences in absorption profiles. Although an
IVIVC can be defined with a minimum of two formulations
with different release rates, three or more formulations with
different release rates are recommended in order to establish
a more robust relationship.
– Predictability of the IVIVC should be assessed. An average
absolute percent prediction error of 110% or less for Cmax and
AUC is preferred.
Use of IVIVC in Post-approval Change Justification
Use of Biowaiver Options in Post-approval Changes for
IR and MR Products. The following section on biowaivers is
written based on the current US FDA guidance(s) and perti-
nent CFRs. The Biopharmaceutical Classification System
(BCS) and other related guidances are in the process of being
(or soon will be) updated; therefore, guidelines to request
biowaivers may change accordingly in the future.
Regulatory Applications of Biowaivers. In many cases,
in vivo bioequivalence studies can be replaced by in vitro
dissolution studies in regulatory applications. The application
can be based on BCS or IVIVC biowaivers or simply on a
dissolution profile comparison. Both BCS and IVIVC
biowaivers can be utilized to support post-approval changes
in drug product composition, manufacturing site, or produc-
tion method.
Approval of new, lower strengths or some minor changes
to the drug product can sometimes be applied for and justified
based solely on the dissolution profile comparison without the
need for IVIVC or BCS-based biowaivers. In such cases, in
order to assure bioequivalence, the new dose strength or new
formulation should have a similar dissolution profile to that of
the drug formulation already on the market. Examples of
biowaiver applications are
& Biowaivers for comparative bioavailability studies in sup-
port of a New Drug Application
& Biowaivers for comparative bioavailability studies in sup-
port of the bioequivalence of subsequent-entry products to
the US market
& Biowaivers for bridging studies where the formulation to be
marketed is different from the formulation used in the piv-
otal clinical trials
& Biowaivers for studies in support of significant post-approv-
al changes and product line extensions
General Considerations. Waiver of in vivo studies for
different strengths of a drug product can be granted under
Section 320.22(d)(2) when the following requirements are
meet: (1) the drug product is in the same dosage form, but in
a different strength; (2) this different strength is proportionally
similar in its active and inactive ingredients to the strength of
the product for which the same manufacturer has conducted
an appropriate in vivo study; (3) there is evidence of linear
kinetics in the proposed dosing range; and (4) the new
strength meets appropriate in vitro dissolution and similarity
f2 tests.
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The “proportionally similar” requirement is defined in
the following ways:
& All active and inactive ingredients are in exactly the same
proportion between different strengths (e.g., a tablet of 50-
mg strength has all the inactive ingredients, exactly half that
of a tablet of 100-mg strength, and twice that of a tablet of
25-mg strength).
& Active and inactive ingredients are not in exactly the same
proportion between different strengths as stated above, but
the ratios of inactive ingredients to the total weight of the
dosage form are within the limits defined by the SUPAC-IR
and SUPAC-MR guidances up to and including level II.
& For drug products, where the amount of the active drug
substance in the dosage form is relatively low compared to
the excipients, the total weight of the dosage form remains
nearly the same for all strengths (within +10% of the total
weight of the strength on which a bio-study was performed),
the same inactive ingredients are used for all strengths, and
the change in any strength is obtained by altering the
amount of the active ingredients and one or more of the
inactive ingredients. The changes in the inactive ingredients
are within the limits defined by the SUPAC-IR and SUPAC-
MR guidances up to and including level II.
& In interpreting the guidance, it is important to note that
combination products (i.e., bilayer tablets, etc.) are consid-
ered to be one formulation even though they consist of two
separate layers with different formulations. In assessing the
proportional similarity of the different strengths, all compo-
nents of both layers have to be proportionally similar. The
fact that only one layer is proportionally similar and the
other is not clearly indicates that the product (whole tablet)
is not proportionally similar. In many instances, there might
be interactions among the different tablet layers that might
be different across different strengths due to the different
sizes of the layers and the varying amounts of excipients
present in each layer.
& Exceptions to the above definitions may be possible, if
adequate justification is provided.
Biowaivers for IR and MR solid oral products can be
classified under three major categories, as described in the
following section:
Biowaivers Without n IVIVC. Immediate-Release For-
mulations (Capsules, Tablets, and Suspensions): Dissolution
profiles should be generated for all strengths. If an appropri-
ate dissolution method has been established and the dissolu-
tion results indicate that the dissolution characteristics of the
product are not dependent on the pH and product strength,
then dissolution profiles in one medium are usually sufficient
to support waivers of in vivo testing. Otherwise, dissolution
data in at least three media (e.g., pH 1.2, 4.5, and 6.8) are
needed. The f2 test should be used to compare profiles from
the different strengths of the product. An f2 value >50 indi-
cates a sufficiently similar dissolution profile such that further
in vivo studies are not needed. For an f2 value <50, further
discussions with the appropriate review division may help
determine whether an in vivo study is needed. The f2 approach
is not suitable for rapidly dissolving drug products (e.g., >85%
dissolved in 15 min or less).
Biowaivers for Lower-/Higher-Strength Products: When
several strengths of the same dosage form are proportionally
similar in their active and inactive ingredients, an in vivo
waiver can be granted for the lower strength(s) based on
comparability of the dissolution profiles and an acceptable
in vivo BA or BE study on the highest strength. Similarly, it
is also possible to get a waiver for a higher strength based on
the assessment of (1) clinical safety and/or efficacy data on the
proposed dose and the need for the higher strength, (2) line-
arity of the pharmacokinetics over the therapeutic dose range,
(3) the higher strength is compositionally proportionally sim-
ilar to the lower strength,1 and (4) the same dissolution pro-
cedures being used for all strengths and similar dissolution
results are obtained.
Biowaivers for Over-encapsulation of Clinical Trial For-
mulations: During the course of drug development, sponsors
sometimes have to blind the formulations that they use in the
clinical trials. In certain situations, the only difference between
the market and clinical trial formulation is that the tablet mix
or the tablet itself is put into a capsule. This is done mainly for
blinding purposes. It is thus possible to obtain a waiver for the
bioequivalence study that links the market and clinical trial
formulation provided that no other excipients are added to the
capsule that are known to affect the release of the active drug
from the capsule. The waiver of this in vivo bioequivalence
study is granted based on the comparability of the dissolution
profile in three media: 0.1 N HCl and phosphate buffers
pH 4.5 and 6.8.
Biowaivers During Scale-Up and Post-approval Changes:
Certain formulation changes in components and composition,
scale-up, manufacturing site change, manufacturing process,
or equipment changes may be made post-approval. Depend-
ing on the possible impact of the manufacturing change on the
release of the active ingredient and its bioavailability from
that formulation, certain manufacturing changes for IR prod-
ucts can be approved solely based on comparability of the
dissolution profiles between the post-change and pre-change
formulations. Information on biowaivers (and the require-
ments of in vitro dissolution and in vivo BE studies) for
immediate-release drug products is provided in the FDA’s
SUPAC IR Guidance for Industry: Immediate-Release Solid
Oral Dosage Forms: Scale-Up and Post-approval Changes:
Chemistry, Manufacturing, and Controls, In Vitro Dissolution
Testing, and In Vivo Bioequivalence Documentation (31).
Biowaivers for Modified-Release Formulations: Informa-
tion on alternative methods to demonstrate bioequivalence
for modified-release drug products approved in the presence
of specified post-approval changes is provided in an FDA
guidance for industry entitled SUPAC-MR: Modified-Release
Solid Oral Dosage Forms: Scale-Up and Post-approval
Changes: Chemistry, Manufacturing, and Controls, In Vitro
Dissolution Testing, and In Vivo Bioequivalence Documenta-
tion (32). The same principles described in the guidance may
be applied to pre- and post-approval changes.
Beaded Capsules: Lower/Higher Strength: For extended-
release beaded capsules where the strength differs only in the
1 If the formulations of all the strengths are not compositionally
proportional, a biowaiver can be granted for the middle strengths
based on acceptable BA or BE data for both the highest and the
lowest strengths in the in vitro multimedia comparative dissolution
profiles and f2 data.
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number of beads containing the active moiety, a single-dose,
fasting PK or BE study, as appropriate, should be carried out
on the highest strength, with a request for a waiver of the
in vivo studies for the lower strengths based on comparative
dissolution profiles. The dissolution profile for each strength
should be generated using the recommended dissolution
method. If the dissolution method has not been finalized, then
dissolution profiles should be generated in at least three media
(e.g., pH 1.2, 4.5, and 6.8). In vivo BE studies for higher
strengths may not be necessary based on (1) clinical safety
and/or efficacy data on the proposed dose and the need for the
higher strength, (2) linearity of pharmacokinetics over the
therapeutic dose range, and (3) the same dissolution proce-
dures being used for all strengths and similar dissolution re-
sults obtained. The f2 test can be used to compare profiles for
the different strengths of the product. An f2 value of >50 can
be used to confirm that further in vivo studies are not needed.
ER Tablets—Lower Strength: For extended-release tab-
lets, when the drug product is in the same dosage form but in a
different strength and when (1) drug exhibits linear PK, (2)
the various strengths are proportionally similar in its active
and inactive ingredients,2 and (3) has the same drug release
mechanism, an in vivo BA or BE determination of one or
more lower strengths can be demonstrated based on dissolu-
tion profile comparisons, with an in vivo BA or BE study only
on the highest strength. The dissolution profile for each
strength should be generated using the recommended disso-
lution method. If the dissolution method has not been final-
ized, then dissolution profiles should be generated in at least
three media (e.g., pH 1.2, 4.5, and 6.8). The dissolution profile
should be generated on the test and reference products of all
strengths using the same dissolution test conditions.
Biowaivers Based on IVIVC. With a predictive IVIVC,
in vitro dissolution would not only be a tool to assure the
consistent performance of the formulation from lot to lot but
would also become a surrogate for the in vivo performance of
the drug product. The ability to predict the plasma concentra-
tion time profile from in vitro data will reduce the number of
studies required to approve and maintain a drug product on
the market, therefore reducing the regulatory burden on the
pharmaceutical industry.
Once an IVIVC has been established, it is possible to
waive the requirements for bioavailability/bioequivalence
studies. For example, a biowaiver can be granted for pre-
and post-approval level 3 manufacturing and process changes,
approval of lower strengths, or level 3 formulation changes
with complete removal or replacement of excipients (both
non-release and release-controlling excipients).
If the IVIVC is developed with the highest strength,
waivers for changes made with the lowest strengths are possi-
ble if these strengths are compositionally proportional or
qualitatively the same, the in vitro dissolution profiles are
similar, and all the strengths have the same release
mechanism.
An IVIVC cannot be used to gain the approval of (a) a
new formulation with a different release mechanism, (b) a
dosage strength higher or lower than the doses that have been
shown to be safe and effective in the clinical trials, (c) another
sponsor’s oral controlled-release product even with the same
release mechanism, and (d) a formulation change involving an
excipient that will significantly affect drug absorption.
For modified-release formulations, it is possible to obtain
in vivo bioavailability/bioequivalence waivers based on
in vitro dissolution for changes in formulations that usually
require an in vivo study. The regulatory criteria for granting
biowaivers are outlined in the previously cited FDA guidance
on this topic. Basically, the mean predicted Cmax and AUC
from the respective in vitro dissolution profiles should differ
from each other by more than 20%.
For information on IVIVC waivers, refer to the FDA
Guidance for Industry: Extended-Release Oral Dosage
Forms: Development, Evaluation, and Application of In
Vitro/In Vivo Correlations (33).
Biowaivers Based on the Biopharmaceutical Classification
System. The BCS is a scientific framework for classifying drug
substances based on two fundamental properties of a drug
substance, i.e., its aqueous solubility and intestinal permeabil-
ity. A drug substance can have either a high or low aqueous
solubility as well as either a high or low intestinal permeability.
In addition, the BCS also takes into account the drug product
dissolution which can be either rapid or slow. Thus, the BCS
takes into account three major factors that govern the rate and
extent of drug absorption from IR solid oral dosage forms:
dissolution, solubility, and intestinal permeability (including
gastric stability).
In the USA, a BCS-based biowaiver is limited only to
class 1 (high solubility–high permeability) drug substances. A
BCS biowaiver is acceptable for BCS class I drugs formulated
as rapidly dissolving immediate-release products. In that case,
the application may be based on in vitro dissolution and
permeability data together with scientific justification of linear
pharmacokinetics, a proof that the drug does not have a
narrow therapeutic index and that the excipients do not have
pharmacokinetic interactions with the drug.
BCS-based biowaivers are meant to reduce the need for
establishing in vivo bioavailability/bioequivalence in situations
where in vitro data may be considered to provide a reasonable
estimate of the in vivo performance of the immediate-release
solid oral pharmaceutical drug products. For information on
BCS waivers, refer to the FDA Guidance for Industry: Waiver
of In Vivo Bioavailability and Bioequivalence Studies for
Immediate-Release Solid Oral Dosage Forms Based on a
Biopharmaceutics Classification System.
The approach outlined in the BCS guidance can be used
to justify biowaivers for highly soluble and highly permeable
drug substances (i.e., class 1) in IR solid oral dosage forms that
exhibit rapid in vitro dissolution using the recommended test
methods (21 CFR 320.22(e)). A drug substance is considered
highly soluble when the highest dose strength is soluble in
250 mL or less of aqueous media over the pH range of 1–
7.5. In the absence of evidence suggesting instability in the
gastrointestinal tract, a drug substance is considered to be
highly permeable when the extent of absorption in humans is
2 If the formulations of all the strengths are not compositionally
proportional, a biowaiver can be granted for the middle strength(s)
based on acceptable BA or BE data as appropriate, for both the
highest and the lowest strengths, and the in vitro multimedia disso-
lution comparison profiles and f2 data.
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determined to be 90% or more of an administered dose based
on a mass balance determination or in comparison to an
intravenous reference dose. Alternatively, nonhuman systems
capable of predicting the extent of drug absorption in humans
can be used (e.g., in vitro epithelial cell culture methods). In
the BCS guidance, an IR drug product is considered rapidly
dissolving when no less than 85% of the labeled amount of the
drug substance dissolves within 30 min, using USPApparatus I
at 100 rpm (or Apparatus II at 50 rpm) in a volume of 900 mL
or less in each of the following media: (1) 0.1 N HCl or
simulated gastric fluid USP without enzymes; (2) a pH 4.5
buffer; and (3) a pH 6.8 buffer or simulated intestinal fluid
USP without enzymes.
Examples of cases where this guidance applies are
& Biowaivers for comparative bioavailability studies in sup-
port of New Drug Application
& Biowaivers for comparative bioavailability studies in sup-
port of the bioequivalence of subsequent-entry products to
the US market
& Biowaivers for bridging studies where the formulation to be
marketed is different from the formulation used in the piv-
otal clinical trials
& Biowaivers for studies in support of significant post-approv-
al changes and product line extensions
In all these cases, samples should be collected at a
sufficient number of intervals to characterize the dissolu-
tion profile of the drug product (e.g., 10, 15, 20, and
30 min). When comparing the test and reference products,
dissolution profiles should be compared using a similarity
factor (f2). Two dissolution profiles are considered similar
when the f2 value is ≥50. However, when both test and
reference products dissolve 85% or more of the label
amount of the drug in <15 min using all three dissolution
media recommended above, the profile comparison with
an f2 test is unnecessary.
Improvements in the Control of Product Scale-Up
and Validation
Introduction
Process validation was often achieved by the statistically
unsound practice of demonstrating that three batches could be
made, within specifications, at commercial scale and at the
commercial manufacturing site. This may or may not have
been preceded by a trial batch to demonstrate the ability to
scale-up.
Current regulatory authority and industry expectations,
however, are for an approach which integrates scale-up and
validation with product development and process understand-
ing. This is aligned with the risk-based development and QbD
approaches discussed in previous sections of this publication.
This can be envisioned as a two-step process. First, use a
scientific, statistics-based system to characterize materials, for-
mulations, and processes and the factors which influence the
potential of a product to meet CQAs during development;
second, connect and utilize this information in the scale-up
and validation process.
The concept of integrating development and validation
activities is addressed in the EMEA Guidance Document on
Process Validation, made effective in September 2001 and
brought more up to date with the FDA Guidance document
“Process Validation, General Principles and Practices,” issued
in January 2011 (34). This document highlights the continuum
from development to commercialization and how knowledge
gained throughout this process should be used to ensure that
the product continues to have the desired CQAs.
Integration with the Development Program
The scale-up of the drug product manufacturing process
needs to be aligned with the rest of the development program.
The mandatory requirement is that scale-up and validation be
completed prior to commercialization, but in practice, aspects
such as meeting the requirements to supply product for the
pivotal clinical program often move the manufacturing pro-
cess scale-up much earlier in the project timeline.
If the intention is to perform pivotal clinical studies with
the to-be-marketed product, then this can provide an anchor
point for the scale-up activities around which the rest of the
program can be constructed.
There are many good reasons to move scale-up prior to
the pivotal studies. It will often make the development pro-
gram simpler and remove the need for a BE study to link the
clinical and commercial formulations; it will also enable the
scientists to gain more knowledge of the commercial process
than if scale-up were performed at the end of the development
process (and provides more time to address any issues identi-
fied) and will provide material for pivotal stability studies.
The negative aspects include, in many cases, the scale-up
activity being performed in parallel with the phase 2 clinical
program, where projects have the highest probability of ter-
mination. In addition, other aspects, such as development of
the API, may need to be moved forward and the range of
doses included in the scale-up program may be wider than
those eventually commercialized.
Scale-Up
For most drug products, practical reasons dictate that the
majority of studies to obtain knowledge about how material
attributes and process parameters impact the CQAs of the
drug product will be performed at a scale significantly smaller
than commercial. However, conclusions relating to acceptable
ranges for process parameters and material attributes need to
be drawn from these studies. Importantly, the impact of ma-
terial attribute differences that may result from multiple sup-
pliers needs to be assessed. The impact of scale on acceptable
ranges will be specific for each attribute or parameter and
needs to be thought through using a combination of acquired
product-specific knowledge and information on the operating
principles of the equipment.
In order to better address the impact of changes in scale,
it is strongly recommended that companies integrate their lab-
, pilot-, and production-scale equipment around specific oper-
ating principles as much as possible. For example, if the pro-
duction facility has top-drive granulators, then use similar, but
smaller, top-drive granulators in development. Similarly, if the
production facility has bin blenders, then use smaller, but
687Development, Scale-Up and Post-approval Control of IR & MR Dosage
equivalent, blenders in development. Introducing a change in
equipment type at the transfer to production scale adds an
unnecessary level of variability.
The scale-up process should be risk-based and begin with a
baseline of product knowledge acquired from prior stages of the
development program. It should also begin with the final com-
mercial process in mind—including an estimated commercial
scale of manufacture and probable manufacturing site. Potential
suppliers of each of the excipients should be identified, with any
differences in physical or quality characteristics (e.g., grade,
density, particle size, crystal habit) fully evaluated in any assess-
ments of risk, and API representative of that which will be used
commercially should be available. If the API development pro-
cess is not at a stage where API is representative of commercial,
then thematerial available for the scale-up activities will become
the target for the commercial process. Whether this is a reason-
able risk to take depends on the specific API and drug product.
The general pattern that the scale-up activities will follow
should be known prior to conducting the risk assessment. The
most typical approach is to perform blocks of studies where
the number of experiments and ranges evaluated decrease as
the scale increases. Therefore, following a risk assessment, the
output will be assessed to determine what can meaningfully be
evaluated at a small scale. A large number of lab-scale batches
are typically conducted as a series of statistical experimental
designs whereby the ranges for parameters are wider than
anticipated at commercial scale. If many parameters are being
evaluated, these may be simple, two-level screening-type de-
signs. The knowledge obtained on the design space from the
lab-scale studies then provides a foundation for a smaller
number of batches at a larger (pilot) scale, with fewer param-
eters and attributes being evaluated and those that are evalu-
ated having narrower ranges. Parameters found not to be
critical at lab scale may not be evaluated at pilot or commer-
cial scale. Statistical designs at pilot scale are typically more
powerful, enabling a more detailed assessment of the design
space to be obtained. Simple designs are adequate to screen
and select variables, whereas more powerful designs allow the
optimization of these same variables.
The assessment of the data from the pilot-scale studies
could include a comparison with the data from lab-scale stud-
ies to characterize the impact of scale. There are several
potential benefits of this. The most obvious one would be
the opportunity to use lab- or pilot-scale experiments, rather
than commercial scale, to assess the impact of desired changes
to a commercial process.
After an assessment of the data from these pilot-scale stud-
ies, the plans for process evaluation at commercial scale are
prepared, with fewer parameters being evaluated and narrower
ranges than pilot scale. In most cases, limitations such as API
availability and cost will restrict evaluations at this scale to a very
small number of batches, which may be made at extremes (e.g.,
corner points of the design space) of the ranges for commercial
manufacture. The number of batches possible is unlikely to be
large enough for a statistical experimental design. The parameters
evaluated should include any parameter thought to be difficult to
assess at a scale smaller than commercial.
A clear understanding of how a process changes with scale
is critical to being able to conduct the risk assessments and
determine which parameters to evaluate at each scale. In some
cases, e.g., milling, a result obtained as the acceptable range for a
parameter at lab scale may be directly transferable to commer-
cial scale, whereas in others, e.g., granulation, the impact of scale
is more complex, and although small-scale studies may show the
extent to which a process is robust, direct conclusions regarding
process parameters such as impeller speeds are not usually
possible. For this reason, continuous unit operations such as
dry granulation are gaining in popularity since scale-up is facil-
itated by the transferability of small-scale data.
Potential interactions between parameters or parameters
and material attributes must also be taken into consideration.
An example of this which is easy to visualize is the interaction
between duration and capacity or duration and material density
for a blending process. An experimental design that includes
assessment of the interactions between both parameters and
material attributes can often uncover important interactions.
Throughout the scale-up process, extensive monitoring of
the batches should be performed. This will be process-depen-
dent, but could include blend uniformity testing at multiple
blending times, extensive stratified sampling for uniformity
during compression or encapsulation, or monitoring of pro-
cesses in real time using PAT techniques. The focus should be
on areas considered to be high potential risks to successful
commercial manufacture. This will add to the body of process
knowledge available.
Validation
The FDAGuidance document “Process Validation—General
Principles and Practices” (34) introduced the concept of three
stages of validation with an emphasis on acquiring and using pro-
cess knowledge in each successive step. The three stages are
Stage 1 Process Design: The commercial manufacturing
process is defined during this stage based on
knowledge gained through development and
scale-up activities.
The development and scale-up activities de-
scribed in earlier sections of this whitepaper ad-
dress stage 1 requirements.
Stage 2 Process Qualification: During this stage, the pro-
cess design is evaluated to determine whether the
process is capable of reproducible commercial
manufacturing.
This is the section which most closely parallels the
concept of making three consecutive successful
batches at commercial scale. The FDA guidance
document (35) refers to the verification that products
can be successfully manufactured at commercial
scale as Process PerformanceQualification andman-
dates that the decision to begin commercial distribu-
tion of a product must be supported by data from
commercial-scale batches. The commercial-scale
batches included in the scale-up of themanufacturing
process could provide the basis for this section, but
the number of batches needed should be specific for
the product and process and additional batches may
be required to verify ranges for example.
Stage 3 Continued Process Verification: Ongoing assur-
ance is gained during routine production that
the process remains in a state of control.
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The third stage of validation relates to data col-
lection during routine production to continuous-
ly monitor the process. The data should be
collected and statistically analyzed to look for
trends. This database also facilitates problem
solving and simplifies trouble shooting. Many
companies were routinely doing this prior to the
FDA Guidance document in order to determine
process capability, anticipate potential problems,
and provide a database which could be statisti-
cally mined in the event of any process trouble-
shooting being needed.
Improvements in Finished Product Testing
Real-Time Testing Approaches
The aim of QbD is to make more effective use of inno-
vative science, technology, and engineering principles in order
to obtain and maintain process knowledge throughout the life
cycle of a product (25).
This knowledge provides the potential for regulatory re-
lief that can be realized starting from initial product approval
(i.e., through replacement of batch end product testing with
RTRT) as well as continued relief throughout the product’s
life cycle (i.e., through flexible introduction of post-approval
changes without prior approval). Identification of CPPs
coupled with a robust control strategy designed to assure
adherence of the design space to its predetermined ranges
involves close to real-time process assessment to ensure that
the process is operating in conditions to deliver predetermined
end product quality, thereby reducing the need, and more
importantly the value, of end product testing. Release based
on manufacture and control within the design space alone,
however, is not sufficient to assure quality of the drug product
during the manufacturing process. In order to support RTRT,
appropriate surrogates for affected CQAs as a function of
quantified in-process parameters and/or material attributes
need to be established and included in release specifications
(25).
Improvements in Post-approval Testing Schemes
Critical parameters identified and monitored at pertinent
junctures of the process as part of a control strategy allow for a
shift in the focus of quality assessment from end product
testing to the testing of surrogate process steps, parameters,
and inputs further upstream that have been demonstrated to
be directly linked with product performance. As previously
mentioned, correlation of a CPP with its specific CQA is
essential when establishing impact and mitigating risk to DP
quality. Once this correlation is determined, optimization ex-
periments can be done to deepen the understanding of the
relationship to the point where correlation evolves into cau-
sation and, ultimately, prediction of a response with certain
factor conditions is possible. Causal relationships between
parameters and quality attributes allow for surrogate substi-
tution of release testing with parameter values further up-
stream of the process . When str iv ing for RTRT,
quantification of the release data needs to be replaced with
quantification of another parameter/value. For example, tra-
ditional dissolution release testing could be replaced by disin-
tegration time determination, if sufficient knowledge is
attained and correlation established.
Incoming raw material specifications can be valuable in
correlating with final drug product quality attributes. This is
especially true when functional excipients are considered. The
effect main excipients have on DP quality should be assessed
during product development. It is here that the theoretical
impact and potential for affect are investigated and demon-
stration of actual impact determined. This is important be-
cause the attributes of the excipient should not be
considered alone (i.e., magnesium stearate can affect dissolu-
tion). Rather, the technology platform (i.e., dry blend versus
wet granulation) should be considered along with the drug
substance characteristics, level of excipient in the composition,
as well as drug load. The collection of physical and chemical
effects allow for a robust understanding of material character-
istics that do indeed affect ultimate quality. Once established,
quantification of the excipient’s specific attribute causing the
response can be established. For example, the particle size
distribution of a disintegrant may be critical for one drug
product due to a relatively high quantity present in the for-
mulation or particle size distribution variability which affects
the way in which the excipient behaves during processing.
Raw material controls represent one of the earliest interven-
tion and control capabilities in a process.
In-process controls are samples taken at various time points
in any unit operation. They are designed to test for a specific
attribute of the current operating step. For example, loss on
drying (LOD) is a traditional method of establishing how much
water is present in a wet granulation and is used to determine
the end point of drying processes. As LOD sampling is known
for its inherent variability based on procedure, operator, and
experience, it highlights that IPCs are only as valuable as the
accuracy of the information they assess. Generally, IPCs are
designed to evaluate the current unit operation quality. When
striving for RTRT, one must consider how a specific IPC affects
not only the current unit operation but the ultimate drug prod-
uct as well. For example, disintegration time (DT) is commonly
used in pharmaceutical compression operations to assess hard-
ness characteristics and the likelihood a tablet will dissolve
within an appropriate time frame in order to support target
dissolution profiles. If it is possible to understand the relation-
ship between DT and dissolution, demonstration can be per-
formed that if the DT specification is met then the resultant
dissolution will be acceptable; one can propose that control
tablet DT is adequate for assuring acceptable drug release.
As discussed in the previous section, there are many
examples of PAT tools used to enhance process knowledge
during pharmaceutical development and production. Howev-
er, when these tools are desired for use as elements of a
control strategy, selection of a particular technology as well
as appropriate placement of probes at relevant operation steps
are decisions that should be made with consideration given to
a specific product/process. RTRT strategy involving PAT
should be individualized based on adequate level of control,
assessment potential with specific CQA for which the technol-
ogy is a surrogate, and quantification potential that will re-
place the traditional end product test to demonstrate
acceptable process progression and ultimate product quality.
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PAT affords innovative methods for retrieving dynamic
process data in real time or close to real time. Ideally, when
developing a control strategy that involves PAT tools, align-
ment with critical process parameters as it relates to the direct
output of a specific unit operation as well as relation to final
product quality should be attained. In short, DoEs establish
the correlation between a process parameter and specific
quality attributes, and PAT provides the means of detection
and/or control of the parameter assuring acceptable quality
output. Positioning of PAT tools in-line, at-line, or off-line can
also be assessed for their potential in identifying, explaining,
and/or managing process variability. For example, PAT tools
such as NIR or Raman can be used during hot melt extrusion
for assessing polymer layer thickness in multi-polymer systems
and the crystal form of the drug (36). When placed online, the
data collected can be used for process adjustment upstream
(via a feedback loops) or downstream (via feed-forward
loops) based upon process knowledge of how the parameter
and related output affect the final product quality.
Developing Improvements that Hold Future Promise
Batch Versus Continuous Processing
Background. Pharmaceutical production can be broken
into two possibilities: batch and continuous. Traditionally,
pharmaceutical production is batch-oriented. True continuous
processing is just being developed to current regulatory stan-
dards and is still relatively unknown in pharmaceutical pro-
duction. Adoption of continuous processing is challenged by
traditional production facilities, operational processes, and
equipment, but offers a mechanism for rationalizing many
current regulatory concepts.
Current pharmaceutical technology is grounded in batch
production processes. Fixed amounts of materials are added
to large blending equipment and mixed as a batch prior to the
next processing step. Production continues in this manner,
with the entire batch completing each process step prior to
continuing to the next operation. This method generally re-
quires relatively large equipment, large operational facilities,
and some risk that any deviation will introduce quality issues
to the entire batch.
While current pharmaceutical production is considered a
batch process, common production trains are often a mix of
batch and semi-continuous operations. Blenders, mixers, and
fluid bed dryers are generally designed to contain the entire
product lot and are obviously batch operations. Units such as
mills, extruders, tablet presses, and fillers can be viewed as
continuous or semi-continuous. Testing is commonly per-
formed over the entire batch, as is QA review and release.
Quality issues at any part of the batch may result in the entire
batch being rejected.
With continuous processing, material is constantly added
and removed from the process train. Multiple activities (e.g.,
dry blending, wetting, granulation, extrusion) can occur simul-
taneously inside a single piece of equipment. Individual con-
tinuous processing equipment generally has a smaller
footprint than its batch equivalent and only contains a small
fraction of the product “batch” at any given time. Batch size
can be flexible and is based on the throughput rate and run
time. With appropriate in-line testing, the process will stop if/
when the product goes outside of the desired quality param-
eters, limiting potential loss. Consequently, continuous pro-
cessing is being explored today by some pharmaceutical
companies and research institutions.
Batch Size. The Food and Drug Administration
21CFR210.3 defines a lot as a batch, or a specific identified
portion of a batch, having uniform character and quality within
specified limits, or, in the case of a drug product produced by
continuous process, it is a specific identified amount produced in
a unit of time or quantity in a manner that assures its having
uniform character and quality within specified limits (37).
Continuous processing equipment matches the raw mate-
rial input with the processed product’s output. The unit will
generate material at a controlled rate until the raw materials
are exhausted or the process is stopped. Batch size is therefore
variable and must be established by the manufacturer. Batch
size is important in controlling potential liability (e.g., product
recalls) and identifying the extent of release and stability
testing required. Limiting a continuous process to a time range
(e.g., 5 h or 5 days), introduction of new lots of raw materials
(e.g., “batch” defined as the amount of product produced
prior to a lot change in any raw material), or desired output
(e.g., 500 kg) are all possible definitions that could be applied
by a manufacturer.
Processors. Throughput with continuous systems is con-
trolled by the equipment size and processing speed. Continu-
ous processing has often meant large-scale equipment capable
of producing metric tons of material a month. Recently, phar-
maceutical equipment manufacturers have begun producing
laboratory- or pilot-scale units for use in development and
short-run production areas where flexibility is the desired
goal. This equipment is often designed with quick-change
product contact parts, allowing rapid production shifts. Small-
er equipment also means the same units used for development
may be adaptable to short-run production, thus eliminating
scaling differences. These smaller units also allow more rapid
prototyping with less material, reducing the cost and time of
developing a design space.
Feeders. Maintaining appropriate control of raw material
inputs is critical for continuous processing. An imbalance in
material entering the unit will cause variation in processing
conditions and output, potentially changing production unifor-
mity. Feed rate control is usually accomplished by the use of
highly accurate loss-in-weight feeders. Modern feeders can feed
as little as 20 g/h and can operate with software capable of
compensating for material powder flow issues inside the hopper.
Process Analytical Technology. PAT is critical to pharma-
ceutical continuous processing. Due to the need to modulate
the process, in-line and real-time product testing with feed-
back loops to the controller is essential. PAT can also be used
at other points in the process, with the potential to drastically
reduce throughput times. For example, PAT tools such as
near-IR could be applied to the raw material hoppers to
provide within-drum and across-lot test data. This could be
expanded to allow for online raw material release, eliminating
or drastically reducing the wait time for chemical testing. PAT
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also increases the need for full electronic batch records to
collate the sensor data streams and maintain correlation with
processing parameters. The value of PAT application along
the continuous process stream is obvious, monitoring product
quality to meet the needs of continuous validation.
Quality by Design. QbD is an integral component of
continuous processing, as is design of experiments. Continu-
ous equipment allows for the effects of changes to processing
speeds and materials to be rapidly assessed. Building the
design space with continuous processing is more rapid due to
the ability to change parameters and produce product more or
less on the fly while consuming smaller amounts of material.
With the low material holdup in most continuous systems,
parameter or material changes can often be evaluated in a
matter of minutes using minimal amounts of material. This
statement will also be true of production systems, although the
quantity of materials will increase with larger units.
Scale-Up. When appropriate-sized equipment is used in
the developmental trials, process scale-up with continuous
systems can be as simplistic as just running the unit for
longer periods of time. This makes all of the design space
data directly applicable to production operations with no
need for extrapolations of the effects of larger equipment
or different operating conditions. If larger equipment is
necessary, more detailed validation can still be accomplished
with less wasted material than under batch conditions.
Production. Production with continuous processing will
resemble scale-up, with a further run time extension. All prior
data are directly relevant and meaningful to the production
operation. Changes to API or excipient can be evaluated
directly on the production unit, but with significantly reduced
risk compared to full-scale batch operations.
Continuous equipment can allow highly flexible operations
with significantly reduced manufacturing floor space. This
equipment will be much more automated than existing batch
systems and could operate in near “lights out” conditions. Ap-
propriate PAT development to allow in-line rawmaterial testing
and release would allow just-in-time raw material deliveries
without the need to wait for QC testing. PATapplied to finished
product coupled with complete electronic batch record informa-
tion and automated data review could allow for real-time online
release, reducing or eliminating the need for manual batch
record review and release. With processors designed for rapid
changeover, it is conceivable to operate in a lean environment
and produce product to meet current consumer demand rather
than to a predefined market forecast.
Systems. Vendors are beginning to produce systems ca-
pable of meeting the demands of continuous processing sys-
tems. Turnkey systems can be purchased for wet granulation
and direct compression tablets, including operations through
compression and coating. Equipment for semi-solids and some
liquids have been developed, although usually as unique one-
up systems. Computer systems capable of handling the wider
data streams generated by modern PAT units, equipment
inputs, and processing system control are more available and
less expensive. These systems are capable of delivering the
concept of continuous process validation. As PAT, comput-
ing systems, and production equipment improve, the poten-
tial for continuous processing equipment will expand.
Issues Affecting Implementation. While significant effort
has been put into the development of continuous process-
ing, commercial implementation is still limited. Gaining
acceptance of PAT and full electronic batch record
implementations has been challenging and is critical for
the implementation of continuous systems. Some applica-
tions, e.g., lyophilization, are not normally applied in a
continuous manner and present special equipment chal-
lenges. Existing capacity in batch facilities and equipment
suggests that the cost of changeover to continuous systems
is relatively high, resulting in pushback from current
stakeholders. The lack of availability of these systems in
developmental laboratories also reduces the likelihood of
rapid implementation. The pharmaceutical industry is still
waiting on the advent of breakthrough product or two to
bring continuous processing to the forefront.
Glossary of Scientific Terms Used in This Whitepaper
ANDA Abbreviated new drug application
API Active pharmaceutical ingredient
APR Annual product review
BA Bioavailability
BACPAC Bulk active compound post-approval changes
BCS Biopharmaceutics Classification System
BE Bioequivalence
CANDA Computer-aided NDA
CBE Changes being effected
CMA Critical manufacturing attribute
CMC Chemistry, manufacturing and control
CMDh Coordination Group for Mutual Recognition &
Decentralized Procedures—Human (Canadian
Ministry of Health)
CPP Critical process parameter
CPV Continued process verification
CQA Critical quality attribute




EMEA European Medicines Agency
FDA Food & Drug Administration
FMEA Failure mode effect analysis
FRC Functionally related characteristics
HMI Human–machine interface
HPLC High-performance liquid chromatography
ICH International Conference on Harmonization
IPC In-process control
IR Immediate release
IVIVC In vitro–in vivo correlation
LOD Loss on drying
MAPP Manual of Policies & Procedures (FDA)
MR Modified release or extended release
MSPC Multivariate statistical process control
MVDA Multivariate data analysis
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NDA New drug application
NIR Near-infrared
NOC Notice of change (Canadian Ministry of Health)
NOR Normal operating range
OFAT One factor at a time
PAR Proven acceptable ranges
PAS Prior approval supplement
PAT Process analytical technology
PCA Principal component analysis
PLS Partial least squares
PNOC Post-notice of compliance changes (Canadian
Ministry of Health)
PSD Particle size distribution
QbD Quality by design
QRM Quality risk management
QTPP Quality target product profile
RTRT Real-time release testing
SCADA Supervisory Control and Data Acquisition
TPP Target product profile
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